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ชื่อวิทยานิพนธ  ความหลากหลายของยีน Transthyretin และ ApoE  ในคนไทย 
ผูเขียน สุภลักษณ  ศรีนวล 
สาขาวิชา ชีวเคม ี
ปการศึกษา 2550 
 
บทคัดยอ 
 
Amyloid β (Aβ) เปนองคประกอบหลักของ senile plaques ในผูปวยโรคอัล-
ไซเมอร โดยพบวา amyloid precursor protein (APP) ที่สรางมากขึ้นซ่ึงชักนําใหเกิด Aβ เพ่ิม
สูงขึ้นนั้นรวมทั้งการกลายพันธุของยีนทีเ่กี่ยวของกับการสรางโปรตีน amyloid กเ็ปนสาเหตุหลกั
ของการเกิดกอน amyloid ที่อวัยวะตางๆโดยเฉพาะสมองดวย ดังน้ันคนที่เปนโรคพันธุกรรมบาง
โรคเชน Down’s syndrome (trisomy 21) ซ่ึงมีโครโมโซมที่ 21 อยู 3 แทงจึงมีความเสี่ยงสูงตอ
การพัฒนาไปสูการเกิดโรคอัลไซเมอรได ในบรรดาโปรตีนที่พบในพลาสมานั้น apolipoprotein E 
(ApoE) และ transthyretrin (TTR) เปนโปรตีนที่มีความสําคญัที่เกี่ยวของกับการเกิดกอน 
amyloid โดยมีการยืนยันถึงความสัมพันธระหวางอัลลลีของยีน ApoE โดยเฉพาะ ApoE-ε4 กับ
โรคอัลไซเมอร พบวาความสัมพันธน้ีมีความแตกตางในระหวางกลุมเชื้อชาติ สําหรับประเทศ
ไทยนั้นเคยปรากฏรายงานของลักษณะจโีนไทปของยีน ApoE เฉพาะในกลุมคนปกติและกลุม
ผูสูงอายุเทานั้น สวนความหลากหลายของยีน TTR ก็พบในทํานองเดียวกัน โดยพบวา TTR 
เปนองคประกอบหลักของการเกิดกอน amyloid  โดยเฉพาะอยางยิ่ง ณ บริเวณปลายประสาท
และนําไปสูอาการในกลุม familial amyloid polyneuropathy (FAP), familial amyloid 
cardiomyopathy (FAC) และ senile systemic amyloidosis ซ่ึงมีความแตกตางกันในระหวาง
กลุมเชื้อชาตเิชนกัน โดยพบวา TTR เกิดการกลายพันธุไดมากกวา 80 ตําแหนง ดวยความถี่
ของการเกิดการกลายพันธุและอาการทางคลินิก มีความแตกตางกันไปในระหวางกลุมเชื้อชาติ
สําหรับในประเทศไทยความหลากหลายของยีน TTR ยังไมเคยมีปรากฏรายงานมากอน ดังน้ัน
ในงานวิทยานพินธครั้งน้ีจึงไดทําการศึกษาความหลากหลายของยีนและคนหา ApoE และ TTR 
ในกลุมคนไทยที่มีความเสีย่งสูงตอการเกิดโรคอัลไซเมอร ซ่ึงในการศึกษาจีโนไทปของยีน ApoE 
โดยวิธี Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-
RFLP) น้ันไดทําการศึกษาจาก Genomic DNA ที่เตรียมไดจากกลุมคนปกติจํานวน 48 ราย 
(อายุเฉลี่ย 60± ป), กลุมผูปวยโรค Down’s syndrome (อายุเฉลีย่ 12.64 ± 5.57 ป เปนเพศ
ชาย 19 ราย และ เพศหญิง 14 ราย), กลุมผูปวยทีไ่มใชผูปวย Down’s syndrome(DS) แตมี
ความเสี่ยงสูงตอการเกิดโรคอัลไซเมอร (other Alzheimer Disease High Risk; ADHR) จํานวน 
55 ราย (อายุเฉลี่ย 46.78 ± 11.45 ป เปนเพศชาย 19 ราย และ เพศหญิง 36 ราย) และกลุม
 iv 
ควบคุมของกลุม ADHR จํานวน 101 ราย (อายุเฉลีย่ 45.31±10.81 ป เปนเพศชาย 31 ราย 
และ เพศหญิง 70 ราย)  
จากการศึกษาทั้ง 4 กลุมตัวอยางชี้ใหเห็นวา ε3/ε3 เปนจีโนไทปที่พบมากใน
ทั้ง 4 กลุม สอดคลองกับที่เคยมีการรายงานมาแลวในกลุมคนสุขภาพดีและกลุมผูปวยโรค 
Down’s syndrome ที่มีอายุในเชื้อชาติอ่ืนๆ และยังพบอัลลลี ε3 มากในทั้ง 4 กลุมตัวอยางอีก
ดวย การศึกษาในครั้งน้ีไมพบ homozygous ε2/ε2 ในทั้ง 4 กลุมตัวอยางซึ่งแตกตางจากที่เคย
มีรายงานในกลุมคนไทยที่มีสุขภาพดี แตเหมือนกับรายงานที่เคยมีในการศึกษากลุมคนไทย
สูงอายุทั้งที่เปนและไมเปนโรคสมองเสื่อม ซ่ึงจากรายงานในครั้งน้ันคาดวา ε2/ε2 อาจมีบทบาท
ในการขัดขวางการเกิดโรคสมองเสื่อมในกลุม DS และกลุมสูงอายุ การศึกษาในวทิยานิพนธครัง้
น้ียังพบความถี่ของ homozygous ε4/ε4 ในกลุม DS เปน 3 เทาของกลุมคนปกติ ซ่ึงเม่ือ
เปรียบเทียบแลวแตกตางจาก DS ในกลุมเชื้อชาติอ่ืนๆ ทําใหเชื่อไดวากลุมคนไทยที่เปนโรค DS 
น้ี จะมีการพัฒนาไปสูโรคอัลไซเมอรไดเร็วกวาในกลุมเชื้อชาติอ่ืนๆ เม่ือเปรียบเทียบกลุม ADHR 
กับกลุมควบคมุของ ADHR พบวาจีโนไทป ε2/ε3, ε3/ε3, ε2/ε4 และ อัลลลี ε2, ε3 มีความถี่
เชนเดียวกบักลุมเชื้อชาติอ่ืนๆรวมทั้งยังเหมือนกับกลุมคนปกติและกลุม DS อีกดวย สวน
ความถี่ของจีโนไทป ε3/ε4 , ε4/ε4 และอัลลลี ε4 ในกลุม ADHR มีความแตกตางจากกลุม
ควบคุมของ ADHR โดยพบความถีข่อง ε3/ε4 และ ε4/ε4 เปน 3 เทา และอัลลีล ε4 เปน 2 
เทาของกลุมควบคุมของ ADHR คาดไดวากลุม ADHR น้ีนาจะมีความเสี่ยงสูงตอการพัฒนาไป
เปนโรคสมองเสื่อมและโรคอัลไซเมอร 
จากการศึกษาการกลายพนัธุของยีน TTR บริเวณ exon1, exon2 และ exon4 
ของกลุมตัวอยางจํานวน 173 ราย และการศึกษายีน TTR บริเวณ exon1 และ exon4 ของ
ตัวอยาง AD paraffin-embedded โดยวิธี Single-Stranded Conformation Polymorphism 
(SSCP) พบความผิดปกตใินการเคลื่อนที่ในกระแสไฟฟาของ TTR exon1 จํานวน 3 ราย และ 
TTR exon4 จํานวน 2 ราย  ผลการศึกษาลําดับเบสของ TTR exon1 ที่ผิดปกติน้ัน พบวาเกิด
การแทนที่เบส Cytosine โดย Guanine ซ่ึงสงผลใหเกิด Single Nucleotide Polymorphism 
(SNP) ใน intron1 ณ ลําดับนิวคลีโอไทดที่ 22 จากปลาย 3′ของ TTR exon1   
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ABSTRACT 
 
Amyloid β (Aβ) is the major component of senile plaques found in 
Alzheimer's disease (AD). An increase production of amyloid precursor protein 
(APP), which leads to high levels of Aβ and also mutation of some other amyloid 
related proteins is the major cause in formation of the amyloid plaque in organs 
particular brain. Therefore, people with some genetic disorder such as Down’s 
symdrome (trisomy 21) who contain three copies of chromosome, thus, have high risk 
in developing the AD. Among proteins in plasma, apolipoprotein E (ApoE) and 
transthyretrin (TTR) are two of those important proteins that related to the amyloid 
plaque formation. The association of the ApoE gene alleles in particular ApoE-ε4 with 
AD has been supported and it is different among the ethic backgrounds. In Thailand, 
genotype of ApoE was reported in only normal and elderly groups (Senanarong et al., 
2001). Similarly, genetic variation of TTR which is the main constituent of amyloid 
that deposits preferentially in peripheral nerve and leads to familial amyloid 
polyneuropathy (FAP), familial amyloid cardiomyopathy (FAC) and senile systemic 
amyloidosis, is also different among population. More than 80 mutations of TTR have 
been identified associated to the diseases with frequency and clinical manifestations 
vary among populations. In Thailand, the genetic variation of the TTR gene has never 
been reported. In this thesis, variation of ApoE and TTR genes was examined in Thai 
people with high risk in AD in order to search for and characterize the mutation of the 
genes. Genomic DNAs from 48 normal people (average age is over 60 years), 33 
patients with DS (average age is 12.64 ± 5.57 years; 19 males and 14 females), 55 
cases with other AD high risk (ADHR) (average age is 46.78 ± 11.45 years; 19 males 
 vi 
and 36 females)  and 101 ADHR control (average age is 45.31±10.81 years; 31 males 
and 70 females) were prepared and used in study for ApoE genotype by Polymerase 
Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP). 
The results indicated ε3/ε3 was the most common genotype found in all 
of these four Thai groups, similarly to that previous reported in healthy and elderly DS 
of other ethnics. In addition, ε3 was the most common allele. An absence of the 
homozygous ε2/ε2 in all Thai groups was observed with un-expectation, and it 
differed from that previously reported for Thai healthy however is similar to that 
found in Thai elderly with and without dementia. This might suggest the protective 
role in development of dementia in only DS and elderly. The frequency of 
homozygous ε4/ε4 was three times in Thai DS, different from the DS in other ethnics, 
convincing to faster development of AD in Thai DS. By comparing with control, the 
ADHR showed similar frequencies of ε2/ε3, ε3/ε3, ε2/ε4, ε2 and ε3 to other ethnics 
and also to the normal and the DS groups studied here. The frequency differences 
were only observed in ε3/ε4 and ε4/ε4 genotypes and the ε4 allele. The ε3/ε4 and 
ε4/ε4 were triple and the ε4 allele was double comparing to the control, suggesting to 
high risk in development of dementia and AD in the ADHR group. 
Mutation of the TTR gene in exon1, exon2 and exon4 regions in 173 
Thai people and that in exon1 and exon4 regions in the AD paraffin-embedded 
specimen were determined by Single-stranded conformation polymorphism (SSCP). 
Three and two samples showed abnormal electrophoresis mobility of the exon1 and 
exon4 fragments, respectively. According to nucleotide sequencing, it was revealed 
the abnormality in exon1 fragment was due to the C→G substitution single nucleotide 
polymorphism (SNP) in TTR intron1 at position 22 downstream to the 3′end of the 
TTR exon1.  
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CHAPTER 1 
 
INTRODUCTION 
 
Introduction 
 
Amyloid β (Aβ) is the major component of senile plaques found in 
Alzheimer's disease (AD).The Aβ also exists in a soluble form in physiological fluids 
such as cerebrospinal fluid (CSF) and plasma as well as in the conditioned media of 
different cultured cell lines (Smith and Anderton, 1994; Haass et al., 1992; Seubert 
et al., 1992). The mechanism by which Aβ forms the fibrils is unclear. But several 
evidences suggested that the fibril formation is a critical step in the pathogenesis of 
AD. CSF contains several factors that promote the solubility, transport and clearance 
of Aβ,mainly, two important proteins are apolipoprotein E (ApoE) and transthyretrin 
(TTR). 
Several evidences pointed to an active role of ApoE and TTR in fibril 
formation in the brain. ApoE binds to β-peptide with high affinity in vitro (Strittmatter 
et al., 1993), promotes Aβ fibrillogenesis in vitro and induces accumulation of the β-
amyloid peptide in cultured vascular smooth muscle (Ma et al., 1994; Wisniewski et 
al., 1994; Mazur-Koleka et al., 1995), whereas, TTR inhibits and prevents this fibril 
formation (Mazur-Koleka et al., 1995; Schwarzman et al., 1994). TTR in CSF was 
shown negative correlation with the degree of dementia in the patients with AD, while 
it has been shown associated with ApoE in AD. The ApoE levels increased in lumbar 
CSF in cases with normal aging and more extensively with AD (Merched et al., 1997; 
Lindh et al., 1997; Song et al., 1997). The TTR levels also increased with aging but 
decreased with AD. 
The AD was first discovered by Alois Alzheimer. This disease occurs 
mainly after age 65 and is the most common cause of dementia in the elderly. Memory 
loss, mainly the recent memory, and impaired judgment are the classic symptoms of 
AD. Normally the nerve cells in brain are arranged in an orderly manner. In persons 
with AD the cells are extremely disorganized and dysfunctional. As the brain cells 
stop working, part of the brain dies. This is the cause of memory loss. On 
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chromosome 21 of human, the gene coding for the amyoid precursor protein (APP), 
which is a precursor of the Aβ, is located. A genetic fault in this gene was identified 
as the first theorized cause of AD. People with DS are trisomy, therefore the patients 
have three instead of two sets of this gene in cell, leading to high production of APP 
and, in the consequence, high levels of the Aβ peptide. This is the reason why some 
people with DS develop AD at unusually younger ages. With build up of amyloid 
protein, the presence of neuritic plaques and neurofibrillary tangles is also seen in 
people with DS.  
Among populations, association of the ApoE-ε4 allele with AD was 
different among ethnic background. In Caucasians, the ApoE allele is a risk factor of 
cerebral amlyoid angiopathy (CAA) and it would be independent of AD (Mazur-
Koleka et al., 1995; Schwarzman et al., 1994). Whereas, in Japanese, the strong 
association existing between ApoE-ε4 allele and AD (Serot et al., 1994). In addition, 
mutation in ApoE gene has been recently reported (Kambo et al., 1999; Scacchi et al., 
2003), and higher risk of developing AD was associated with the mutation (Scacchi 
et al., 2003). In Thailand, genotype of ApoE was reported in only 2 groups of people, 
normal and elderly people. Distribution of ApoE genotype in the elderly people was 
similar to that reported in other ethic groups (Senanarong et al., 2001), and with 
bearing of ApoE-ε4 allele to the increase of the risk of developing dementia.  
In persons with DS, a large variation of ApoE allele frequencies has 
been found (Anello et al., 2001; Royston et al., 1994 ; van Gool et al., 1995), most 
likely reflecting the different geographic origins. The relation between ApoE-ε4 and 
the risk and onset of AD has been controversial. Some studies showed an increased 
risk of AD associated with the ApoE-ε4 allele in persons with DS (Deb et al., 2000; 
Prasher et al., 1997; Schupf and Segievsky, 2002), but others could not confirm this 
(Anello et al., 2001; Lucarelli et al., 2003; van Gool et al., 1995). There is evidence 
that ApoE-ε2 is associated with increased longevity in some studies of DS (Prasher, 
1992; Prasher et al., 1997; Tyrrell et al., 1998), but a protective effect  on AD (Lai et 
al., 1999; Rubinsztein et al., 1999; Tyrrell et al., 1998) could not be confirm by all 
(Deb et al., 2000). The ApoE-ε4 allele has been associated further with early mortality 
(Folin et al., 2003), but a meta-analysis based on data from 538 persons with DS 
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showed no significant evidence for an increased mortality of ApoE-ε4 homozygotes 
with DS (Edland et al., 1997). From biochemical perspective, one may assume that 
ApoE-ε4 is involved in dementia through the amyloid pathway (Lott and Head, 2005; 
Margallo-Lana et al., 2004). ApoE-ε4 may interact with the Aβ peptide to increase 
aggregation of the Aβ. However, on the assumption that having three copies of APP 
may overwhelm the effect of the ApoE-ε4 on Aβ metabolism, possible make the 
ApoE genotype less relevant for persons with DS in comparison to the general 
population. 
Similarly to ApoE, genetic variation of TTR gene among populations 
has been reported. TTR Val30Met (V30M), is a major cause of familial amyloid 
polyneuropathy (FAP) in Portuguess (Saraiva et al., 1995), Swedish (Andersson et al., 
1976) and Japanese (Araki et al., 1980), whereas, the Val122Ile (V122I) variant, 
carried by 3.9% of the African-Americans, is the most common cause of familial 
amyloid cardiomyopathy (FAC) (Jacobson et al., 1992). In French, up to 10 point 
mutations of the TTR gene have been identified so far and all led to development of 
the same pattern of neuropathy (Planté-Bordeneuve et al., 1998). Thus, information of 
the genetic variation is essential for an effective diagnosis and specifically treatment 
of the patient group. 
TTR has been demonstrated as the most abundant protein component of 
amyloid fibrils (Costa et al., 1978) that lead to a group of diseases called amyloidosis. 
Typical manifestations of the disease caused by deposition of the TTR amyloids are 
peripheral neuropathy, cardiomyopathy, carpal tunnel syndrome, and vitreous 
opacities. Up to date, over 100 genetic TTR variants derived from a single amino acid 
substitutions have been reported (for review, sees Schwarzman et al., 2004) and up to 
80 are related to amyloidosis with most clinical syndromes, familial amyloidotic 
polyneuropathy (FAP) that TTR amyloids deposition is systemically in the peripheral 
nervous system, and familial amyloidosis cardiomyopathy (FAC). In addition, the 
native TTR with an entirely normal amino acid sequence can also find in patients with 
senile systemic amyloidosis (Westermark et al., 1990). 
FAP and FAC were described as the autosomal dominant inherited 
diseases caused by different single point mutations of the TTR gene. However, role of 
TTR mutations in the amyloidogenesis is not well understood and different mutations 
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are often associated with distinct clinical symptoms. Several reports suggested that 
point mutations of TTR gene could change conformation of the protein to an 
intermediate oligomer with an extensive β-sheet. Without a proper therapy, TTR 
amyloidosis can result in the fatal course, leading to death within 10 to 15 years. 
Orthopic liver transplantation is the most powerful therapy available nowadays. The 
treatment was shown to virtually eliminate TTR variant from plasma of the patients 
with FAP. However, it does not provide a practical means of treatment for a large 
number of patients. Moreover, the cardiac amyloidosis could progress and its effect on 
autonomic dysfunction has not been established (Adams et al., 2000). Thus, other 
therapeutic strategies, e.g. a specific blocking an expression of the mutant TTR gene 
and stabilization of native conformation of the TTR with chemicals such as 4′-deoxy-
4′-iodoxorubicin (IDOX), tetracycline and nitrophenols (Cardoso et al., 2003) are 
being pursued. Frequency and clinical manifestations including age of onset, sex ratio 
and duration of the disease generated by deposition of the TTR amyloids are varied 
among populations. For examples, among the pathogenic TTR identified so far, V30M 
is the most frequent variant (Saraiva, 1984, 2001), vastly found in Portuguese and 
Swedish. In contrast, heterogeneity of the point mutations of TTR that result in more 
than 20 different amino acid substitutions including V30M has been reported among 
Japanese (Andersson, 1970; Araki, 1984; Ikeda et al., 2002). Similar to that observed 
in French (Planté-Bordeneuve et al., 1998), heterogeneity incident of Leu55Pro 
(L55P) and V122I on FAC was reported in many other populations including 
Taiwanese and African Americans (Jacobson et al., 1992; Yamamoto et al., 1994), 
putting these people to a significant risk for congestive heart failure. In Thailand, no 
genetic variation of the TTR gene has been studied so far. To accomplish for direct 
diagnosis and specific treatment for Thai patients, information on type and 
characteristics of TTR variant distribute in the area is essential.  
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Review of Literatures 
 
1. ApolipoproteinE (ApoE) 
 
1.1 General 
 
ApoE is a glycoprotein that is important in lipid storage, transport, and 
metabolism (Mahley, 1988). It is mainly synthesized in liver, but also found in 
peripheral and central nervous systems, including of brain. ApoE has long been of 
interest in medicine, but its importance in neuroscience has increased dramatically 
since the identification of the ε4 allele of the ApoE gene as a major risk factor for the 
development of late-onset AD in elderly (Saunders et al., 1993; Strittmatter et al., 
1993). This discovery led to a growing number of studies examining the role of the 
ApoE gene in normal brain function and cognition, as well as in disorders such as AD, 
brain injury, and stroke (Higgins et al., 1997; Horsburgh et al., 2000). Polymorphisms 
of the ApoE gene are associated with significant alterations in brain morphology 
(Plassman et al., 1997) and cognitive functioning, including attention (Greenwood et 
al., 2000) and memory (Bondi et al., 1995). Studies of ApoE thus are focused with 
aim to reveal information relevant to the genetics of attention and memory in normal 
individuals. At the same time, such studies may identify cognitive and neural changes 
that may be characteristic of preclinical stages of AD.  
Genetically, the ApoE-ε4 allele is associated with both familial late 
onset and sporadic AD and atherosclerosis (Greenow et al., 2005; Lane and Farlow, 
2005; Tanzi and Bertram, 2005). AD patients carrying the ApoE-ε4 allele have more 
profound deposition of Aβ in their brains than those carrying other ApoE alleles (de la 
Torre, 2002; Farrer et al., 1997). Considerable evidence supports that ApoE4 
increases the risk of AD by accelerating the plaque formation and by impairing the 
neurons. ApoE4 appears to modulate processing of APP and production of Aβ 
through both the LDL receptor-related protein pathway and domain interaction (Ye 
et al., 2005). Strong correlation of ApoE-ε4 allele with dyslipidemia and 
atherosclerosis, the major underlying mechanism of coronary heart disease, has been 
demonstrated (Gregg and Brewer, 1998). Human ApoE4 represents a dual risk factor 
for these two major degenerative diseases. 
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NH2-Lys-Val-Glu-Gln-Ala-Val-Glu-Thr-Glu-Pro-Glu-Pro-Glu-Leu-Arg-Gln-Gln- 
Thr-Glu-Trp-Gln-Ser-Gly-Gln-Arg-Trp-Glu-Leu-Ala-Leu-Gly-Arg-Phe-Trp-Asp- 
Tyr-Leu-Arg-Trp-Val-Gln-Thr-Leu-Ser-Glu-Gln-Val-Gln-Glu-Glu-Leu-Leu-Ser-
Ser-Gln-Val-Thr-Gln-Glu-Leu-Arg-Ala-Leu-Met-Asp-Glu-Thr-Met-Lys-Glu-Leu- 
Lys-Ala-Tyr-Lys-Ser-Glu-Leu-Glu-Glu-Gln-Leu-Thr-Pro-Val-Ala-Glu-Glu-Thr- 
Arg-Ala-Arg-Leu-Ser-Lys-Glu-Leu-Gln-Ala-Ala-Gln-Ala-Arg-Leu-Gly-Ala-Asp-
Met-Glu-Asp-Val-Cys-Gly-Arg-Leu-Val-Gln-Tyr-Arg-Gly-Glu-Val-Gln-Ala-Met-
Leu-Gly-Gln-Ser-Thr-Glu-Glu-Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-
Leu-Arg-Lys-Arg-Leu-Leu-Arg-Asp-Ala-Asp-Asp-Leu-Gln-Lys-Arg-Leu-Ala-Val-
Tyr-Gln-Ala-Gly-Ala-Arg-Glu-Gly-Ala-Glu-Arg-Gly-Leu-Ser-Ala-Ile-Arg-Glu-
Arg-Leu-Gly-Pro-Leu-Val-Glu-Gln-Gly-Arg-Val-Arg-Ala-Ala-Thr-Val-Gly-Ser-
Leu-Ala-Gly-Gln-Pro-Leu-Gln-Glu-Arg-Ala-Gln-Ala-Trp-Gly-Glu-Arg-Leu-Arg-
Ala-Arg-Met-Glu-Glu-Met-Gly-Ser-Arg-Thr-Arg-Asp-Arg-Leu-Asp-Glu-Val-Lys-
Glu-Gln-Val-Ala-Glu-Val-Arg-Ala-Lys-Leu-Glu-Glu-Gln-Ala-Gln-Gln-Ile-Arg-
Leu-Gln-Ala-Glu-Ala-Phe-Gln-Ala-Arg-Leu-Lys-Ser-Trp-Phe-Glu-Pro-Leu-Val-
Glu-Ash-Met-Gln-Arg-Gln-Trp-Ala-Gly-Leu-Val-Glu-Lys-Val-Gln-Ala-Ala-Val-
Gly-Thr-Ser-Ala-Ala-Pro-Val-Pro-Ser-Asp-Asn-His-COOH 
 
 
Figure 1.1 Amino acid sequence of human ApoE3 (wildtype) isoform 
(Cys112/Arg 158) 
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1.2 General structure and chemical properties of human ApoE 
 
Human ApoE is a protein consisting of 299 amino acid residues (Figure 
1.1) with a molecular mass of 34 kDa. It serves as a ligand for the low density 
lipoprotein (LDL) receptor family, and through this interaction, plays a major role in 
modulating plasma lipoprotein metabolism (Mahley, 1988; Weisgraber, 1994). ApoE 
is polymorphic with three major isoforms (ApoE2, ApoE3, and ApoE4) and a number 
of rare variants (Mahley, 1988; Rall & Mahley, 1992; Weisgraber, 1994). Majority of 
the ApoE isoforms differ at positions 112 and 158. ApoE3 contains cysteine and 
arginine at those two positions respectively, while ApoE2 contains cysteine and 
ApoE4 contains arginine at both positions (Weisgraber et al., 1981) (Figure 1.2). This 
polymorphism has functional consequences. ApoE2 binds defectively to the LDL 
receptor, resulting in type III hyperlipoproteinemia, which is a lipid disorder 
associated with premature heart disease (Mahley & Rall, 1995). This defective 
binding results from the substitution of arginine by cysteine at position 158 and is 
mediated indirectly, through rearrangement of salt bridges (Wilson et al., 1994; Dong 
et al., 1996). ApoE4 is associated with increased lipid levels and an increased risk of 
cardiovascular disease (Utermann et al., 1984; Eichner et al., 1993; Luc et al., 1994). 
The allele is also a major risk factor for AD (Corder et al., 1993; Saunders et al., 
1993; Strittmatter et al., 1993) and other forms of neurodegeneration (Mayeux et al., 
1995; Slooter et al., 1997; Teasdale et al., 1997). 
ApoE is composed of two functionally distinct domains (Aggerbeck 
et al., 1988; Wetterau et al., 1988). Thrombin cleavage of ApoE results in a 22 kDa 
amino-terminal domain (residues 1–191) and a shorter 10 kDa carboxy-terminal 
fragment (residues 216–299) (Figure 1.3 A, B) (Innerarity et al., 1983). The region 
spanning from residues 136-160 of the 22 kDa (N-terminal) domain is rich in basic 
amino acids and is involved in LDL receptor binding (Innerarity et al., 1983; Dyer and 
Curtiss, 1991; Weisgraber, 1994 and Siest et al., 1995) (Figure 1.3 B) (Innerarity et 
al., 1983; Dyer and Curtiss, 1991; Weisgraber, 1994 and Siest et al., 1995). The 
10 kDa (C-terminal) fragment carries the major lipid-binding determinants of ApoE 
(Weisgraber, 1990) and is responsible for the tetramer forming of the intact ApoE 
protein (Aggerbeck et al., 1988). The C-terminal domain, which is predicted to 
contain three helices, is less well known. The first two helices, comprising residues 
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203-223 and residues 225-266, are class A type, and the third helix, consisting of 
residues 268-289, is a G* helix (Nolte and Atkinson, 1992). The G* helix and part of 
the end of the second helix is expected play a key role in lipid binding and lipid 
interaction in ApoE-containing lipoproteins (Sparrow et al., 1992) (Figure 1.3 B)  
The ApoE4 binds preferentially to VLDL and the interaction between 
Arg-61 and Glu-255 was suggested stabilize an extended helical structure in the 
carboxyl terminus to accommodate a larger less-curved VLDL surface (Dong and 
Weisgraber, 1996). The C-terminal domain of ApoE beyond residue 191, i.e. residues 
203-223, 225-266, and 268-289, contains three predicted helices (Figure 1.3 A) 
(Wilson et al., 1991; De Pauw et al., 1997). The end of the second helix was proposed 
play a key role in lipid binding in ApoE and lipoprotein interaction (Westerlund and 
Weisgraber, 1993; Weisgraber, 1994). The third helix (G* helix) (Figure 1.3 B) 
induces the aggregation of C-terminus that becomes monomer after the polar/charged 
mutation of five amino acid residues, i.e. Phe257, Trp264, Val269, Leu279, and 
Val287 (Fan et al., 2004). Choy et al. (2004) have also shown intermolecular coiled-
coil helical formation in the C-terminal domain. The C-terminal region of ApoE was 
also suggested interact with Aβ in forming neurofibrillary tangle (Huang et al., 2001). 
ApoE4 is one of the major proteins associated with Aβ plaques (Wisniewski et al., 
1994, Puglielli et al., 2003). The role of ApoE in the molecular pathogenesis of AD 
might be related to its isoform-specific interactions with lipids or Aβ aggregates. 
However, the structural characters of ApoE isoforms that may lead to the differences 
in molecular pathogenesis of AD remain poorly understood. 
Like other soluble apolipoproteins, ApoE is stable in both lipid 
associated and lipid-free aqueous states. The helices in the four helix bundle of ApoE 
are amphipathic, classified as G* by Segrest et al. (1994) (Figure 1.3 B), placing them 
between the typical globular amphipathic helices and the helices typical of other 
apolipoproteins. The amphipathic nature and particular character of the apolipoprotein 
helices are thought to be responsible for their lipid-binding properties (Segrest et al., 
1994). It has been hypothesized that the amino-terminal four-helix bundle undergoes a 
significant conformational change, opening to expose the hydrophobic core to interact 
with lipid (Weisgraber, 1994). Molecular area measurements at an air:water interface 
support this model (Weisgraber, 1994). Although the major lipid-binding elements of 
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ApoE are contained in the C-terminal domain, the 22 kDa (N-terminal) domain, the 10 
kDa (C-terminal) fragment, and the intact protein will remodel spherical vesicles of 
dimyristoylphosphatidylcholine (DMPC) and other phospholipids into bilayer 
discoidal particles (Innerarity et al., 1979, 1983). However, the conformation of ApoE 
on these phospholipid discs is still unknown. Two models have been proposed: the 
“picket fence” model, in which the amphipathic helices are aligned parallel to the 
phospholipid acyl chains (De Pauw et al., 1995), and the “belt” model, in which the 
helices lie perpendicular to the acyl chains (Raussens et al., 1998). In addition to its 
roles in cardiovascular and neurodegenerative diseases, ApoE has been implicated in 
immuno-regulation (Hui et al., 1980; Avila et al., 1982), intracellular cholesterol 
metabolism modulation (Reyland and Williams, 1991), and cell growth and migration 
control (Ishigami et al., 1998). These diverse roles underscore the importance of 
ApoE as a potential target for therapeutic agents and highlight the need for a better 
understanding of the relationship of its structure and function.  
 
 
10
 
 
Figure 1.2 Structure of ApoE isoforms 
There are three isoforms of ApoE by which differ from each other only 
a single amino acid substitution at residues 112 and 158. 
ApoE2 (Cys112/Cys158), ApoE3 (wildtype; Cys112/Arg158), and 
ApoE4 (Arg112/Arg158). 
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Figure 1.3 (A) Three dimensional structure (3D) of human ApoE   
Two domains of ApoE, N-terminal and C-terminal domains, are shown 
in figure. The N-terminal domain contains four helices that arrange into 
anti-parallel elongated bundles, while the C-terminal domain contains 
three helices. The LDL receptor binding region in the N-terminal 
domain, and the major lipid-binding site in the C-terminal also are 
shown. 
(Source: Chou et al., 2006) 
 
(B) Structures of class A and class G* amphipathic helices. 
The class A amphipathic helix structure of the first two helices, i.e. 
residues 203-233 and residues 225-266, and the class G* helix 
structure of the third helix, residues 268-289, of ApoE C-terminal 
domain are shown. The Aβ binding and inhibitory regions are also 
shown. 
(Source: for review, sees Tomiyama et al., 1999) 
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1.3 Gene structure of human ApoE 
 
Apolipoprotein E (ApoE) is a component of various classes of plasma 
lipoproteins in all mammals (Mahley et al., 1979 and 1984). It is a single chain 
polypeptide (MW. 34,000 kDa) of 299 amino acids (Rall et al., 1982) that is initially 
synthesized with an 18-residue signal peptide that is co-translationally removed later 
(Paik et al., 1985). The amino acid and the mRNA nucleotide sequences are known 
for both in human (Rall et al., 1982; McLean et al., 1984) and rat (McLean et al., 
1983). The major site of synthesis is liver, but relatively abundant levels of ApoE 
mRNA have been detected in many extrahepatic tissues, including  brain and adrenals 
(Elshourbagy et al., 1985).  
The gene coding for ApoE locates on chromosome 19 (19q13.2), 
consisting of four exons and three introns (Figure 1.4) (McLean et al., 1984). All 
introns begin with the nucleotides GT and end with the nucleotides AG, which is 
consistent with the consensus sequence for exon-intron splice junctions for eukaryotic 
genes (Breathnach et al., 1978). Lengths of the exons are 44, 66, 193, and 860 
nucleotides, and that of the introns are 760, 1092, and 582 nucleotides (McLean et al., 
1984). The overall ApoE gene is 3597 nucleotides, which encodes mRNA of 1163 
nucleotides.  
The nucleotide sequence of the 5' flanking region of the ApoE gene 
adjacent to the transcription initiation site revealed several potentially important 
sequence elements. It contains the sequence T-A-T-A-A-T-T (Figure 1.5) that is 
homologous to the "TATA box" sequence has been identified as a component of the 
promoter region for most eukaryotic genes (Paik et al., 1985). In addition, two major 
inverted repeated sequences are located within 150 nucleotides adjacent to the mRNA 
start site. The proximal element is located between nucleotides -76 and -46, and the 
distal element is located between nucleotides -144 and -108. Large number of GC 
base pairs in both proximal and distal elements sequences suggested these 
palindrome-like structures are the stable naturally occurring elements (Figure 1.5).  
In the introns and the proximal flanking regions of the ApoE gene, 
there are four segments of Alu repeated sequences ranging from 280 to 324 
nucleotides. Two of these sequences are located in the second intron, while another 
two locate in the non-transcribed flanking regions closely to both ends of the gene 
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(Figure 1.6). Upon alignment for maximum homology of nucleotide sequence, 
individual Alu sequences show 81%-90% of identity (Paik et al., 1985). 
 
 
 
15
 
 
 
 
 
 
 
 
Figure 1.4 The ApoE gene structure 
Gene of ApoE comprises 4 exons and 3 introns. Close boxes with 
Exon1, Exon2, Exon3 and Exon4 on top are ApoE exon 1, 2, 3 and 4, 
respectively. Line with Intron1, Intron2 and Intron3 underneath are 
ApoE intron1, 2 and 3, respectively. 
 
5′ 3′ Exon1 Exon2 Exon3 Exon4
Intron1 Intron2 Intron3 
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Figure 1.5 Transcription initiation site and 5' flanking region of the ApoE 
gene. 
Nucleotide sequences of the proximal 5' region adjacent to the 
transcription initiation site (A) and of the first exon (B) of the ApoE 
gene. Numbers indicate nucleotide positions relative to the initiation 
site (position 1). Bar indicates the TATA box. Inverted repeated 
sequences are shown with all potential base pairs. G-T base pairs 
indicated by a colon. 
(Source: Paik et al., 1985) 
A 
B 
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Figure 1.6  Alu family sequences in the human ApoE gene.  
The ApoE gene with relative positions of exons (solid boxes, upper 
line) and Alu sequences (shaded boxes, lower line) are indicated. 
Nucleotide sequence positions of the first and last nucleotide of each 
element relative to transcription initiation site (position 1) are shown 
above the lines. Lengths of sequence elements are shown below the 
lines. Arrows show orientation of the Alu sequences relative to the 
coding strand of the ApoE gene. Roman numerals indicate the 
individual Alu sequence family members. 
(Source: Paik et al., 1985). 
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1.4 Role of ApoE  
 
1.4.1 ApoE in plasma 
 
Plasma lipoproteins are usually divided into five groups i.e. 
chylomicrons, very-low-density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), low-density lipoproteins (LDL) and high-density lipoproteins 
(HDL). Chylomicrons, the largest lipoproteins synthesized in the small intestine, 
transport dietary cholesterol and triglyceride to the liver and peripheral tissues. 
VLDLs, the second largest lipoproteins, are synthesized in the liver and secreted to 
distribute triglycerides to peripheral tissues. VLDLs are also metabolized by 
lipoprotein lipase into the remnant lipoprotein, IDL. The biological role of IDL is 
unclear. Most IDLs are further metabolized by lipase and produce the smaller 
cholesterol-rich lipoproteins, LDLs. LDLs, in turn, transport liver-synthesized 
cholesterol to peripheral tissues. In peripheral tissues, as well as in the liver, LDL 
binds to the LDL receptor and is taken up by endocytosis. HDLs, the smallest 
lipoproteins synthesized in the liver and the small intestine and also produced in the 
metabolic pathway including chylomicrons and VLDLs, participate in reverse 
cholesterol transport from peripheral tissues to the liver (for review, sees Beffert et al., 
2004). 
Each lipoprotein contains several specific apolipoproteins, such as 
ApoA (AI, AII and AIV), ApoB, ApoC (CI, CII and CIII) and ApoE. ApoE is a 
constituent of chylomicrons, VLDLs, IDLs and a subclass of HDLs, but not LDLs. It 
functions as a ligand for several lipoprotein receptors. Such as, the chylomicron 
remnant that contains the remaining triglyceride and cholesterol binds to ApoE 
receptor(s) in the liver and is taken up by receptor-mediated endocytosis. ApoE has 
multiple amphipathic helices, enabling it to interact with hydrophobic lipid particles 
and provide them with the hydrophilicity required for their transport in the blood 
(Weisgraber, 1994; Segrest et al; 1994). The C-terminus of ApoE was proposed to be 
a major lipid binding region (Figure 1.3 A) (Weisgraber, 1994; Segrest et al; 1994). 
Due to its hydrophobicity, the recombinant C-terminal fragment of ApoE tends to 
aggregate into amyloid-like fibrils (Wisniewski et al., 1995). However, ApoE does not 
exist as a free form in biological fluids.  
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1.4.2 ApoE in brain 
 
ApoE is a ligand for all members of the LDL receptor (LDLR) family 
(for review, sees Beffert et al., 2004) and a constituent of lipoprotein particles that 
transport lipids throughout the circulation and between cells. In the nervous system, 
non-neuronal cell types, most are astroglia and microglia, are the primary producers of 
ApoE, while neurons preferentially express the receptors for ApoE. Amongst the 
ApoE isoforms, the ε4 is at greater risk for developing coronary artery disease and 
late-onset AD, a devastating age related neurodegenerative disorder (Corder et al., 
1993). However, precisely how ApoE isoforms differentially affect an individual’s 
risk for developing AD is under intense debate. Proposed mechanisms include roles 
for ApoE in cholesterol transport and synapse formation, modulation of neurite 
outgrowth and synaptic plasticity, destabilization of microtubules, amyloid clearance 
and fibril formation by direct binding of the Aβ peptide, and impairment of ApoE 
receptor-dependent protective signals that promote neuronal survival and synaptic 
plasticity.  
ApoE is present in abundance in the brain as well as in the CSF. Lipid-
associated ApoE binds to LDL receptor family members on the neuronal cell surface 
where it has been shown to modulate neurite outgrowth in an isoform-specific manner 
(Nathan et al., 1994; Nathan et al., 1995). ApoE-ε2 and ApoE-ε3 isoforms induce 
neurite extension in neurons, whereas ApoE-ε4 inhibits outgrowth. Blockade of ApoE 
receptors with the receptor-associated protein eliminates this effect on neurite 
extension (Holtzman et al., 1995). Furthermore, strong in vitro synapse formation in 
neuronal cultures is dependent on glia-derived ApoE-cholesterol complex (Mauch et 
al., 2001). These lead to hypothesize that neuronal plasticity is modulated by 
transporting lipid into neurons through specific receptors (Figure 1.7). 
A hallmark of AD is the deposition of Aβ, which derives from the APP 
by sequential proteolytic cleavage, in senile plaques in the brain (Hardy and Allsop, 
1991). The ultimate processing step involves intra-membranous cleavage by the 
presenilins and is affected by the cholesterol content of the membrane. Depletion of 
cellular cholesterol reduces the formation of neurotoxic Aβ protein (Simons et al., 
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1998). ApoE can also bind Aβ directly (Strittmatter et al., 1993), thereby possibly 
contributing to its clearance and degradation in a process that may involve lipoprotein 
receptors (Rebeck et al., 1993). In mice, plaque formation is dependent on the 
presence of ApoE (Bales et al., 1997) and can be influenced by reintroducting human 
ApoE (Bales et al., 1999; Holtzman et al., 1999). 
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Figure 1.7  Physiological and hypothetical roles of ApoE in brain 
ApoE is secreted by glial cells (Boyles et al., 1985; Boyles et al., 
1989), and ApoE receptors are abundantly expressed on neurons. ApoE 
secretion by the glia serves, on one hand, to supply the neurons with the 
cholesterol necessary for synapse formation, thereby liberating 
considerable metabolic and biosynthetic capacity for other functions. 
This may have contributed to the rapid increase of brain size during the 
evolution of mammals. On the other hand, however, ApoE may also 
interfere with other important functions that are routed through the 
same receptors. The Reelin signaling pathway is likely just one 
example. Functional impairment of Reelin signaling would negatively 
impact synaptic plasticity and thus potentially adversely affect neuronal 
survival. 
(Source: for review, sees Beffert et al., 2004) 
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1.5 ApoE genotype and late-onset AD 
 
AD is a progressive, neurodegenerative disorder with the principal 
clinical symptom of dementia. It is characterized by three major pathological changes 
in brain, particularly in cerebral cortex and hippocampus. These are neuronal loss, 
senile plaques and neurofibrillary tangles. Senile plaques consist of extracellular 
amyloid deposits surrounded by dystrophic neurites, activated microglia and activated 
astrocytes. The principal component of this amyloid is Aβ. Neurofibrillary tangles, 
which accumulate in the cytoplasm of degenerating neurons, are composed of 
insoluble twisted filaments of abnormally phosphoryrated tau protein. Senile plaque 
formation is observed only in AD, DS and normal aging, whereas neurofibrillary 
tangles occur widely in numerous neurodegenerative disorders that are not 
accompanied by amyloid deposition. In DS, which features of neuropathology are 
indistinguishable from that of AD in younger ages, the deposition of amyloid has been 
shown to precede the appearance of neurofibrillary tangles and dementia. Thus, 
amyloid deposition has been thought more likely to be a cause of AD than 
neurofibrillary tangles.  
In 1993, it was proposed that ApoE4 is a genetic risk factor for late-
onset familial AD (Corder et al., 1993). The proportion of the late-onset AD increased 
from 20% with no copy of ε4 to 47% with one copy, and to 91% with two copies 
(Corder et al., 1993).  In addition, the mean age of AD onset became younger as the 
ε4 alleles increased from 84.3 years with no copy to 75.5 years with one copy, and to 
68.4 years with two copies (Corder et al., 1993). Not only familial but also sporadic 
late-onset AD was shown associated with the ε4 allele (Saunders et al., 1993). 
Moreover, gender difference in ApoE-associated risk for AD was also reported 
(Payami et al., 1996). A direct comparison of ε4 heterozygous between male and 
female revealed a significant twofold increased risk in women. However, in the 
contrary, ApoE-ε2 allele was demonstrated as a protective against late-onset AD 
(Corder et al., 1994).  
 The neuropathological relationship between ApoE and AD was first 
demonstrated in 1991 (Namba et al., 1991). The ApoE immunoreactivity to all 
cerebral and systemic amyloid types was observed (Wisniewski and Frangione, 1992). 
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At present, the ApoE allele and genotype are recognized as the most important genetic 
risk factor for late-onset AD (Corder et al., 1998). In addition a study revealed the 
influences of ApoE-ε4 allele on pathogenesis of dementia and peripheral neuropathy 
in human immunodeficiency virus (HIV) infection, which elicits the inflammatory 
responses in the central nervous system (CNS) similar to those in AD (Corder et al., 
1998).  
 
1.6 ApoE and Aβ in the pathogenesis of AD 
 
Aβ is produced from its larger precursor APP (Selkoe, 1994), which is 
a glycoprotein with a single transmembrane domain and is expressed in both neural 
and non-neural tissues. The physiological role of APP is not well understood. Aβ is 
constitutively secreted as a soluble form during normal cellular metabolism and is 
detected in CSF and plasma of normal individuals as well as AD patients. There are 
two general pathways, α and β, for APP processing. In the α pathway, APP is cleaved 
within the Aβ sequence by α-secretase. In the β pathway, APP is sequentially cleaved 
at different sites in the extracellular and transmembrane domains by β-secretase and γ-
secretase, respectively. Aβ is generated only in the β pathway as the predominant 
form of 40-amino acid peptide (Aβ1–40). 
The amyloid cascade hypothesis, which was supported by the finding 
of neurotoxic of the exogenous Aβ peptides (Yankner et al., 1990), is at present the 
dominant hypothesis concerning the pathogenesis of AD. A number of studies have 
demonstrated that the neurotoxicity of Aβ is dependent on its aggregation state (Pike 
et al., 1993; Iversen et al., 1995) and requires the assembly of Aβ into amyloid fibrils 
(Lorenzo and Yankner 1994). Length of the hydrophobic C-terminus of Aβ is critical 
in determining the rate of aggregation and the process of Aβ aggregation is a 
nucleation-dependent polymerization which can be accelerated by adding preformed 
aggregates as a seed (Jarrett and Lansbury 1993). Many evidences supported this 
hypothesis including predominantly deposition of the Aβ peptide ending at residue 42 
(Aβ1–42) (Iwatsubo et al., 1994) and alteration of APP processing to produce more 
Aβ1–42 in mutations in APP (chromosome 21), presenilin 1 (chromosome 14) and 
presenilin 2 (chromosome 1) in the early-onset familial AD (Hardy, 1997). According 
 
 
24
to the hypothesis, aggregation of Aβ is enhanced by oxidation of Aβ (Dyrks et al., 
1992) and in the presence of metal ions, such as Zn2+ (Bush et al., 1994). The Aβ 
spontaneously fragments and generates free radical peptides, which may react with 
one another to form aggregates and may attack nerve cell membranes (Hensley et al., 
1994). The aggregated Aβ induces intracellular accumulation of reactive oxygen 
species (Behl et al., 1994) and disruption of cellular Ca2+ homeostasis in neurons 
(Mattson et al., 1992). The former effect was suggested to cause oxidative damage of 
neurons, probably via hydroxyl radical generation (Behl et al., 1994). Then, Aβ 
activates microglias (Meda et al., 1995), which in turn internalize microaggregates of 
Aβ via their scavenger receptors (El Khoury et al., 1996; Paresce et al., 1996), and are 
mobilized in pathological lesions and play role in inflammatory processes associated 
with amyloid plaques. 
However, recently a few novel cascades of Aβ deposition have been 
proposed, including the lysosomal accumulation pathway and the plaque-trapping 
pathway. For the lysosomal accumulation pathway, the internalized ApoE induces 
intracellular accumulation of Aβ by inhibiting lysosomal enzymes and thereby alters 
APP metabolism, causing neuronal degeneration. Once neurons die, intracellular Aβ 
aggregates associated with ApoE become extracellular deposits (Figure 1.8 A). This 
cascade initiated from the fact that the internalized HDL particles containing 
ApoE:Aβ complexes that are thought to be delipidated in the endosomal:lysosomal 
pathway and ApoE and Aβ are expected to be degraded in lysosomes. However, it 
was found that the internalized Aβ was not completely degraded (Ida et al., 1996). 
Although most Aβ peptides were degraded after uptake, but small amounts of the 
peptide accumulated in insoluble fractions of the cells and remained stable for several 
days. Purified ApoE was shown to bind to Aβ with its hydrophobic C-terminal region 
(residues 244–272) in vitro (Strittmatter et al., 1993). Moreover, the C-terminal 
fragment residues 216–299 was shown to aggregate into amyloid-like fibrils in vitro 
and was co-purified with Aβ from senile plaques (Wisniewski et al., 1995). These led 
to speculate that the formation of ApoE:Aβ complexe is resistant to lysozyme.  
It was shown that purified ApoE4 bound to Aβ more avidly than 
ApoE3 (Strittmatter et al., 1993). Although, ApoE3 rather ApoE4 induced 
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accumulation of Aβ in a higher percentage of cells, but the deposits induced by 
ApoE4 were more stable (Mazur-Kolecka et al., 1995). Only cells containing Aβ 
deposits induced by ApoE4 exhibited decreased cellular redox activity (Mazur-
Kolecka et al., 1995). In AD brain, intracellular accumulation of ApoE was correlated 
with intracellular Aβ immuno-reactivity within the same cytoplasmic granules and 
with high expression of gp330: megalin, one of the ApoE receptors (Zheng et al., 
1994). DNA fragmentation was restricted to cells with intracellular Aβ 
immunoreactivity, but was not associated with extracellular Aβ deposition (LaFerla 
et al., 1997). It is likely that the presence of Aβ1–42 facilitates intracellular 
aggregation:accumulation of Aβ and ApoE fragments, resulting in seeding for 
subsequent intracellular Aβ1–40 accumulation. In cultures of cells stably expressing 
APP, internalized Aβ1–42 aggregates induced intracellular accumulation of 
amyloidogenic C-terminal fragments of APP (Yang et al., 1995). This abnormal 
accumulation of amyloidogenic C-terminal fragments of APP has been claimed to 
cause neuronal degeneration.  
Plaque-trapping pathway is another possible pathway of ApoE-
mediated Aβ deposition. In the pathway, ApoE-containing HDL should binds to Aβ1–
42 deposits for the clearance process. However, because Aβ1–42 has a strong 
tendency to aggregate, HDL will be trapped by the plaques instead of removing Aβ 
peptides. The trapped HDL probably mobilizes soluble Aβ1–40 and Aβ1–42 peptides 
to the plaques through ApoE-Aβ interaction. The mobilized Aβ peptides are utilized 
for the growth of the plaques. Cholesterol within the trapped HDL may be removed by 
other, probably nascent HDL particles that contain little core lipid (LaDu et al., 1998). 
Aβ deposition is thus accelerated by the presence of ApoE-containing HDL, and 
ApoE is incorporated into amyloid fibrils (figure 1.8, B). This hypothesis is supported 
by the finding that amyloid-associated ApoE purified from AD brain exists not as free 
molecules but as stable complexes with Aβ fibrils (Naslund et al., 1995). However, 
the observation that immunoreactivity to ApoAI, another constituent of HDL, 
occasionally occurred in senile plaques (Wisniewski et al., 1995) is not inconsistent 
with the hypothesis. 
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Figure 1.8  Models of ApoE-mediated Aβ deposition.  
(A) The lysosomal accumulation pathway: ApoE-containing HDL is 
internalized by neurons by receptor-mediated endocytosis. ApoE:Aβ 
complexes are resistant to lysosomal enzymes and thereby aggregate 
and accumulate intracellularly in which subsequently altered APP 
metabolism and thus neuronal degeneration. Once neurons die, 
intracellular Aβ aggregates become extracellular deposits.          
(Source: Tomiyama et al., 1999)  
(B) The plaque-trapping pathway: ApoE-containing HDL binds to 
extracellular Aβ1–42 deposits to clear them, but is instead trapped by 
the plaques. The trapped HDL mobilizes soluble Aβ peptides (mainly 
Aβ1–40) to the plaques via ApoE:Aβ interaction, resulting in enhanced 
deposition of Aβ. (Source: Tomiyama et al.,1999) 
 
 
27
2. Transthyretin (TTR) 
 
2.1 General 
 
TTR is one of the three major thyroid hormone binding proteins found 
in the plasma of larger mammals. It was first found in both human serum and 
cerebrospinal fluid (CSF) (Kabat et al., 1942 a, b). The liver represents the main 
source of synthesis, while choroid plexus and retina produce only small amount of 
TTR. In addition to binding to thyroid hormones, both 3, 5, 3′, 5′-tetraiodothyronine 
(L-thyroxine or T4) and 3, 5, 3′-triiodothyronine (T3), TTR binds virtually all of 
serum retinol-binding protein (RBP). The general protein structure of TTR is a 
tetramer of identical subunits (Blake et al., 1978) with highly content of β-structure, 
which contributes to extraordinary stability of the molecule (Hanlon et al., 1971; 
Branch et al., 1972). Association of two dimers results in a tetramer structure with 
four of eight-stranded β-sheets.  
  
2.2 Structure and chemical properties of TTR 
 
TTR is a globular plasma protein comprising four identical subunits 
(Blake et al., 1978). It has a molecular mass of ~55 kDa and a subunit mass of ~14 
kDa. In human, the TTR subunit consists of 127 amino acid residues (Figure 1.9) 
(Kanda et al., 1974). Most of these amino acid residues are arranged into eight 
stranded β-sheets, and only 5% of them were found in a short α-helix portion (Figure 
1.10 A) (Blake et al., 1974). Similarly to albumin but differ from thyroxine-binding 
globulin (TBG), TTR is not glycosylated. Heterogeneity of TTR observed in several 
animal species (Miller, 1963; Baker et al., 1966; Muto and Goodman, 1972; Taylor 
et al., 1975; Bhat et al., 1997; Harm et al., 1991). It was suggested as resulted from 
other modifications including dihydroxylation, phosphorylation, cysteine-glycine 
conjugation and glutathionylation (Terazaki et al., 1998). Moreover, heterogeneity of 
TTR resulted from complex formation of the protein with retinol binding protein 
(RBP) was also observed (Glover, 1973; Kopelman et al., 1976). 
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The three-dimentional structure of TTR purified from human serum 
has been determined by X-ray diffraction at both 2.5 Å (Blake and Oatley, 1977; 
Wojtczak, 1997) and 1.8 Å resolutions (Blake et al., 1978). It showed that about 45% 
of the amino acid residues of each TTR monomer are organized into eight β-sheets, 
which form into two four-strand β-sheets denoting as DAGH and CBEF. These eight 
strands of the β-sheet, then, form a β sandwich structure connected by the A-B loops 
(Blake et al., 1978). A short α-helix was found located at the end of strand E (Figure 
1.10 B). The rest of amino acid residues were located in seven loops that connect the 
eight β-strands, segments of N-terminus (10 amino acid residues) and C-terminus (5 
amino acid residues) (Hamilton et al., 1993) located outside core structure of the 
tetramer. Two monomers of TTR joined edge-to-edge to form a dimer resulted in a 
pair of twisted eight-stranded of the β-sheets, an inner (DAGHH'G'A'D') and an outer 
(CBEFF'E'B'C). The interactions between monomers involve hydrogen bonding 
between two F strands (F, F') and two H strands (H, H'), however, H-strands are more 
extensively hydrogen bonded than the F strands. The tetrameric structure of TTR is 
formed from two dimers via hydrophobic interactions between amino acid residues in 
the A-B loop and the H strand of the opposite dimer (Figure 1.11). High content of β-
structure (Hanlon et al., 1971; Branch et al., 1972), interaction between monomers to 
Figure 1.9  Amino acid sequence of human TTR 
 
NH2-Gly-Pro-Thr-Gly-Thr-Gly-Glu-Ser-Lys-Cys-Pro-Leu-Met-Val-Lys-Val-Leu-
Asp-Ala-Val-Arg-Gly-Ser-Pro-Ala-Ile-Asn-Val-Ala-Val-His-Val-Phe-Arg-Lys-
Ala-Ala-Asp-Asp-Thr-Trp-Glu-Pro-Phe-Ala-Ser-Gly-Lys-Thr-Ser-Glu-Ser-Gly-
Glu-Leu-His-Gly-Leu-Thr-Thr-Glx-Glx-Gln-Phe-Val-Glu-Gly-Ile-Tyr-Lys-Val-
Glu-Ile-Asp-Thr-Lys-Ser-Tyr-Trp-Lys-Ala-Leu-Gly-Ile-Ser-Pro-Phe-His-Glu-His-
Ala-Glu-Val-Val-Phe-Thr-Ala-Asn-Asp-Ser-Gly-Pro-Arg-Arg-Tyr-Thr-Ile-Ala-
Ala-Leu-Leu-Ser-Pro-Tyr-Ser-Tyr-Ser-Thr-Thr-Ala-Val-Val-Thr-Asn-Pro-Lys-
Glu-COOH 
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form dimers and interaction between dimers to form tetramer contribute to an 
extraordinary stability of the TTR. In comparison, TTR in the tetrameric form is less 
stable than the dimer (Blake et al., 1978). 
A large central channel with approximately to 10 Å in diameter and 
50 Å long and with sterically equivalent in thyroid hormone binding, but with differ in 
their relative binding affinities, is formed as a consequence of the tetrahedral 
arrangement of the TTR subunits (between DAGH) (Blake et al., 1978). Amino acid 
residues that involve in ligand binding were located in strand A (residue 14 to 18), D 
(residue 53 to 56) and G and H (residue 105 to 122) (Neumann et al., 2001). The 
chemical nature of the channel consists of three main elements. First, a hydrophilic 
center that forming from the hydroxyl groups of Ser and Thr residues, and associated 
bound-water molecules. Second, a hydrophobic patch that formed by the methyl group 
of Leu, Thr, Ala, Val and a group of charged residue such as Lys, Glu and His at 
which constitute around the entrance to the channel (for review see Blake, 1981; 
Klabunde et al., 2000). And, finally, a negative cooperate binding of two molecules 
thyroid hormones with the amino acid residues inside the channel (Neumann et al., 
2001; Blake et al., 1974). It revealed that only one binding site of TTR is occupied by 
thyroid hormone under physiological condition (Page et al., 1973; Nilsson et al., 
1975). 
The tetrameric form of TTR is stable and non-dissociated even in 
strong acidic or 0.1% sodium dodecyl sulfate (SDS) solution. But at some conditions 
such as at low pH (3.5 to 5.0) or high molar of denaturing agent, e.g. 4 M to 6 M 
guanidine hydrochloride (Guanidine-HCl), TTR tetramer were slowly dissociated into 
monomers (Kelly et al., 1997; Lai et al., 1997). Dissociation into dimers and 
incomplete dissociation into monomers of TTR tetramer were also demonstrated can 
occur in a solution of 5% SDS without heating and in 8 M urea, respectively (Rask 
et al., 1971). In addition, the tetrameric dissociation into monomer of TTR was also 
suggested to occur at pH 7.0 and at nearly physiological ionic strength upon dilution 
to the sub molecular range (Quintas et al., 1997; 1999). TTR lost the T4 binding 
activity when treated with 6 M urea, however, its binding activity could be restored 
when urea was removed out from the protein solution (Raz and Goodmann, 1969). 
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Figure 1.10 Structure of human TTR monomer (A) and dimer (B).  
Each TTR monomer comprises two β-sheets those are formed from 
DAGH and CBEF strands, and one α-helix. Whereas, face-to-face 
interaction of the two β-sheets through a hydrogen bonding between 
HH' and FF' strands is the key for formation of dimer. 
  (Source: Blake et al., 1978)
A 
B 
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Figure 1.11 The ribbon model of TTR Tetramer 
Two dimers of TTR subunits link together via AB loops to form a 
tetramer, and the thyroxin-binding channel was generated from the 
linking of the dimers. 
(Source:  Monaco, 2002) 
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2.3 Gene structure of human TTR 
 
Each human TTR monomer is encoded by a single-copy gene (Sparkes 
et al., 1987) locating on the long arm of chromosome 18 (Wallace et al., 1985). It was 
found span to about 6.9 kilobases (kbp) containing four exons and three introns 
(Figure 1.12) (Sasaki et al., 1985). The nucleotide sequences at 5' and 3' flanking 
exon/intron border regions and introns of the TTR gene have been analyzed (Sasaki et 
al., 1985; Fung et al., 1988; Motojima and Goto., 1990). It showed that nucleotide 
sequence of the TTR exon 1 was 95 base pairs (bp), encoding for twenty amino acid 
residues of a signal peptide and three amino acid residues of the mature protein. 
Whereas, exon 2, exon 3 and exon 4 contain 131, 136 and 254 bp encoding for 44, 45 
and 35 amino acid residues, respectively. The distance between the transcriptional 
initiate site and the polyadenylate (poly (A)) site is 6,931 bp. The sequence of poly 
(A) tail is located 123 bp downstream of the coding region (Sasaki et al., 1985). 
Lengths of the three introns are 934, 2090 and 3308 bp, respectively. The consensus 
sequences for splicing, GT and AG, were found at the boundaries of all three introns 
(Breathnatch et al., 1978). Two sequence copies of Alu family were found in intron 2 
and 3 of the TTR gene, and it was suggested to involve in the gene expression and 
regulation. The repeated sequences at 3' untranslated region were found almost 
identical to the core sequences. However, biological function of these repeated 
sequences is still unknown. The sequence of TTR gene is highly conserved through 
evolution. More than 80% identity in the sequence was reported among the 
mammalian TTRs (Wakasugi et al., 1985; Schreiber and Richardson, 1997). 
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Figure 1.12 Diagram of TTR gene structure 
Close boxes with E1, E2, E3 and E4 on top represent TTR exon 1, 2, 3 
and 4, respectively. Blue line with In1, In2 and In3 underneath 
represent TTR intron1, 2 and 3, respectively. 
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2.4  Synthesis and distribution of TTR 
 
TTR is mainly synthesized in liver (Felding and Fex, 1982) and 
epithelial cells of choroid plexus (Aleshire et al., 1983). In addition, it is also found 
synthesized in other cells including the retinol pigment epithelial cells (Martone et al., 
1988; Herbert et al., 1991; Ong et al., 1994). TTR in blood circulation is mainly 
produced in hepatocytes, and then secreted into the blood (Dickson et al., 1986). It is 
synthesized as a pre-protein with a signal peptide at N-terminus, which is cleaved 
during translocation of the protein into an endoplasmic reticulum (ER), and within the 
ER of hepatocytes, TTR tetramer is formed (Bellovino et al., 1996; 1998). TTR is 
distributed throughout the body and in equilibrium with the interstitial fluid by 
penetrating the capillaries. The plasma level of TTR increases successively after birth 
and reaches 250µg/ml when adult (Smith and Goodman, 1971). However, the 
concentration of plasma TTR decreases after the fifth decade of life. 
TTR in liver is one of a negative acute phase reactant. The rate of TTR 
synthesis decreases during acute phase response to trauma and chronic inflammation 
(Birch and Schreiber, 1986; Milland et al., 1990; Richardson et al., 1998). Low 
concentration of TTR may result in higher concentration of free ligand, e.g. thyroxine 
and retinol, which lead to malnutrition. In addition, it can reflect the metabolic 
competence of body (for reviews see Raghu and Sivakumar, 2004). Although, 
synthesis of TTR by liver may be altered under stress condition, the synthesis of TTR 
in choroid plexus was very slightly affected (Dickson et al., 1982). This indicated that 
the synthesis of TTR in liver and choroid plexus is independently regulated during the 
acute phase response (Dickson et al., 1986). 
Choroid plexus, an epithelial membrane component of blood-brain 
barrier, is the main synthesis site of TTR found in CSF (Cserr, 1971). All of TTR 
synthesis by the choroid plexus is secreted towards the brain and has been proposed to 
be involved in transport of T4, but not T3, from blood to brain (Dickson et al., 1987). 
Localization of TTR in choroid plexus was first demonstrated using an 
immunohistochemical technique (Aleshine et al., 1983), and it was found distributed 
in cytoplasm and epithelial cell of the choroid plexus (Herbert et al., 1986). TTR 
mRNA was located in the epithelial cells prior to being secreted into the CSF 
(Southwell et al., 1993). Its concentration in choroid plexus was much higher than that 
 
 
35
in liver (Schreiber et al., 1990). About 50% of total secreted protein and about 12% of 
the synthesized protein in choroid plexus is TTR (Dickson et al., 1986). In mammal 
and avian, the TTR gene was expressed in the cells of the choroid plexus in early 
stage of embryogenesis before the formation of blood brain-barrier (Southwell et al., 
1991) and during fetal development (Thomas et al., 1988). A correlation between 
growth rate of the brain and expression level of TTR gene was evidence in growing 
animal (Southwell et al., 1991). 
 
2.5 Functions of TTR 
 
The most well-known physiological function of TTR is a protein 
transporter for thyroid hormones and vitamin A. Thyroid hormones, both T4 and T3, 
directly bind to TTR whereas vitamin A (in retinol form) is bound to TTR through the 
mediation of retinol-binding protein (RBP). 
 
2.5.1 as a thyroid hormone distributor protein 
 
TTR is the one of thyroid hormones binding protein in plasma of 
higher vertebrates, besides thyroid hormone binding globulin (TBG) and albumin. In 
human, binding affinity of TTR to thyroid hormones, in particular T4, is less than 
TBG but higher than albumin (for review sees Schreiber and Richardson, 1997). 
About 10-15% (Palha, 2002) and up to 80% (Hagen and Elliot, 1973) of T4 in human 
plasma and in central nervous system, respectively, are bound and transported by 
TTR. Human TTR has higher affinity for T4 than T3, i.e. T4 bound to TTR about 
10 times higher than T3. However, this binding affinity was change during evolution 
of vertebrates (for review see Schreiber and Richardson, 1997; Schreiber et al., 1998) 
TTR has two binding sites for thyroid hormones (Blake et al., 1978). 
At the physiological condition, only one site is occupied by the hormone molecule due 
to the negative cooperativity of thyroid hormone binding. By equilibrium dialysis 
measurement, the association constant (Ka) was 1.0x108 M-1 and 9.5x105 M-1 for the 
first and second ligand binding sites, respectively (Ferguson et al., 1975), suggesting 
that binding of the first ligand was much stronger than the second ligand. This 
cooperative effect is involved in the conformational changes induced by ligand 
binding to TTR molecule (Neumann et al., 2001). By comparing the TTR channel 
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diameter of the two binding sites, it revealed that binding of the hormone to the first 
site can change diameter of the second. The outer and inner pockets of the channel 
(strand A, D and H) were wider while the middle part (strand G) was collapsed 
(Neumann et al., 2001). Therefore, the second hormone molecule bound to the 
binding site with less strength. 
The tissue distribution of TTR synthesis was observed by 
intravenous injection of 125I-labeled T4 to various tissues (Dickson et al., 1987). T4 
was found first strongly accumulation in the choroid plexus. Then, it was transported 
across the blood brain barrier into CSF by binding with TTR (Southwell et al., 1993). 
This revealed the hypothetical mechanisms for T4 transport from blood to brain in 
such a way that T4 enter to the brain by moving across the epithelial cells of choroid 
plexus or moving across the cerebral endothelial cells. In moving across, T4 bound to 
TTR that locates within the choroid plexus or within CSF (Figure 1.13.). In addition, 
as the concentration of TTR in CSF was related to the total concentration of T4 that 
transported to the brain and between tissue and extracellular fluid, the mechanism of 
regulation of T4 level in the brain was proposed. 
 
2.5.2 as a carrier protein for retinol via binding to RBP 
 
TTR also binds and transports vitamin A or retinol through the 
binding to RBP, a vitamin A carrier protein that is a 21-kDa single polypeptide chain 
protein found in plasma of vertebrates. The TTR-RBP complex transports retinol from 
the main storage in liver to target cells in peripheral tissues. It was shown that without 
binding to TTR, RBP can be eliminated by glomerular filtration in kidney because of 
its small molecule. Therefore, the binding of RBP to TTR was thought to prevent the 
loss of RBP and retinol through glomerular filtration in kidney (Kanai et al., 1968; 
Goodman and Raz, 1972). In human plasma, about 40% of TTR circulates as the 
complex with RBP (Smith and Goodman, 1971), while less than 1% circulates as the 
complex with T4 (Woeber and Ingbar, 1968). The complex formation of TTR and 
RBP was found occurred at physiological pH and involved with a hydrophobic 
interaction (Peterson, 1971). The complex dissociated readily at low ionic strength 
and in the presence of 6 M urea.  
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Figure 1.13 The hypothetical mechanisms for the role of TTR within choroid 
plexus in moving T4 from the blood to brain  
The diagram shows the hypothetical routes for T4 movement from 
blood to brain and CSF. T4 may enter the brain by moving across the 
choroid plexus epithelial cell (the upper) or moving across the cerebral 
endothelial cells (the lower). T4 does not undergo deiodination in the 
choroid plexus but conversion of T4 to T3 is occurred within the brain 
tissue by deiodinases.  
(Sources: Southwell et al., 1993; Schreiber and Richardson, 1997) 
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In human plasma, TTR and RBP formed complex with 1:1 molar ratio 
though the in vitro studying suggested more than one binding sites for RBP (one to 
four sites) are on a TTR molecule (Raghu et al., 2003). This was probably due to the 
limit concentration of RBP in comparing to that of TTR. The binding sites for T4 and 
RBP are independent from each other (Eneqvist et al., 2001). This evidenced from 
that binding of RBP did not change the binding capacity of TTR to T4 (Nilsson and 
Peterson, 1971). 
 
2.5.3 Other functions  
 
A thymic hormone-like activity influence of TTR was demonstrated 
in spleen cells of thymectomized rats (Burton et al., 1978, 1985). It indicated that TTR 
possessed immuno-potentiating properties in vitro and in vivo (Burton et al., 1985). 
Induction with TTR enhanced synthesis of IgM, and a decrease in the specific activity 
of thymocyte terminal deoxynucleotidyl transferase was also observed.  Moreover, the 
amino-terminal domain of the TTR molecule was shown containing a property similar 
to T-lymphocytes (Burton et al., 1987).  
TTR has been shown interacting with perlecan, an important 
constituent of basement membranes and connective tissues (Iozzo et al., 1994) and has 
been identified as a common proteoglycan componebt occurring in several types of 
amyloidosis (Kisilevsky et al., 1992; Magnus et al., 1992). It has been proposed that 
the binding of perlecan to TTR depends on hydrophobic interactions between the two 
proteins. Binding of perlecan to TTR resulted in sequestering the protein from the 
retinol-RBP-TTR complex (Smeland et al., 1997), thus affecting metabolism of 
retinol. Moreover, interaction between TTR and perlecan was suggested favor with 
the co-localization of these two proteins in the TTR-associated amyloidotic deposits 
(Smeland et al., 1997). 
Recently, TTR has been reported having the proteolytic activity (Liz 
et al., 2004). It was shown that TTR can proteolytical process the C-terminal of 
apolipoprotein A-1, thus, was suggested may interact with other substrates in vivo 
under physiological and pathological condition. 
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3. Amyloidosis 
Amyloidogenic TTR mutation 
Hereditary TTR amyloidosis is a genetically transmitted disease that 
resulted from mutation of TTR gene (Saraiva et al., 1984). The mutation leads to the 
extracellular deposition of the TTR subunits in tissue as amyloid. The deposition of 
TTR amyloid in peripheral nerve and the heart associated with neuropathy and 
cardiomyopathy, respectively. The most of familial amyloidotic polyneuropathy 
(FAP) are related to the TTR gene point mutation occurring in adult. The most 
frequent variant that incident around the world is Val30Met (V30M; substitution of 
valine by methionine at amino acid position 30). This TTR variant is resulted from 
single mutation of the nucleotide sequence in exon2 in which guanine is substituted by 
adenine (Saraiva et al., 1984). This TTR genetic abnormality presents in Portuguese, 
Swedish, Japanese, Majorca and French (Saraiva et al., 1984; Andersson, 1970; Araki, 
1984; Munar-Ques et al., 1997; Planté-Bordeneuve et al; 1998). The clinical symptom 
of FAP began in the third to forth decade of life with early impairment of temperature, 
pain sensation in feet, autonomic dysfunction, electrocardiographic abnormally 
emaciation and death finally (Andrade, 1952). A few of TTR mutations found related 
to cardiomyopathy without neurological symptom. Among of these, Val122Ile 
(V112I; substitution of valine by isoleucine at amino acid position 112) is the most 
frequent distributed in African Americans (Jacobson et al., 1997). Until now, over 100 
TTR variants were reported and 80 of them are pathogenic and related to amyloidosis 
(Saraiva, 1996). 
Amylodoisis is a group of diseases in which proteins or protein 
fragments change from their native soluble forms into an insoluble fibril called 
“amyloid”. The amyloid fibrils have been found accumulated in a variety of organs 
and tissues of the body including peripheral nerves, kidney, gastrointestinal tract, heart 
and thyroid (Kelly, 1996; Rochet and Lansbury, 2000). The accumulation of large 
amounts of amyloid fibrils can result in damaging of function and structure of organs. 
Up to date, 24 different amyloidogenic proteins have been identified in human, and 
they are associated with several disorders including AD (Selkoe, 1996), Parkinson’s 
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disease (Conway et al., 1998), familial amyloidotic polyneuropathy (FAP) (Costa 
et al., 1978; Mc Cutchen et al., 1995), light chain amyloidosis (Buxbaum and Gallo, 
1999), and dialysis-related amyloidosis (Drueke, 2000). 
The “amyloid” was first used to describe the cerebral corpora 
amylacea, a material that was found during histopathological examination of brain 
(Virchow, 1854), which was later identified as a carbohydrate substance. In 1859, it 
was shown that protein was a component of amyloid (Friedreich and Kelkulé, 1859). 
By detection using Congo red, an amorphous proteinaceous aggregates were identified 
(Bennhold, 1922). The fibrillar ultrastructure of the amyloid fibrils was later revealed 
by electron microscopy (Cohen and Calkins, 1959).  
 
3.1 Nature of amyloid 
 
Amyloid is an insoluble fibrillar protein that extracellularly deposit in 
tissues or organs. The amyloid fibrils can be formed from several different precursor 
proteins that share a common ultrastructure. These proteins exhibit as straight and 
non-branch fibrils with about 7.5 to 10 nm thick but undetermined length, and reveal a 
superficial twist and two protofibrils (Cohen, 1966). The X-ray diffraction showed 
that the fibril has a “cross β” structure in which the constituent strands are arranged 
perpendicular to the long axis of the fibril (Blake and Serpell, 1996). Moreover, the 
amyloid fibril showed uniform tintorial properties including apple green birefringence 
after staining with Congo red (Glenner, 1981; Serpell et al., 1997). The amyloid fibrils 
showed orange colored fluorescence that is most sensitive (Linke, 2000). 
Many mechanisms have been proposed for the conformational change 
of the precursor protein that leads to the fibril formation. These include point mutation 
(Saraiva, 2001; Shastry, 2003), overproduction of the precursor protein (Gillmore 
et al., 2001), change in local pH of membrane, oxidation and proteolytic cleavage 
(Haass and Steiner, 2001). However, several amyloid fibrils have been demonstrated 
forming from the wild type of precursor proteins (Westermark et al., 1986). The 
precursor proteins that adopt a globular folding in their native state require partial 
unfolding of their tertiary structure prior to the fibril formation, while those unfolded 
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in their native state required a transition to an ordered secondary structure (Rochet and 
Lansbury, 2000). 
 
3.2 Classification of amyloid 
 
The amyloid disease can be divided into two groups according to their 
distribution in body, the localized and the systemic amyloidoses. For the localized 
amyloids, the deposition is restricted to one tissue or organ whereas the systemic 
amyloids deposit in many different organs or tissues. All amyloid precursor proteins 
have been identified so far are diverse and unrelated, but produce amyloid deposition 
with beta-fibrillar as a common structure. The specific precursor proteins and their 
classification are listed in Table 1.1 
 
3.3  TTR amyloidosis 
 
TTR is one of the precursor proteins known to form amyloid fibril 
(Damas and Saraiva, 2000) that is associated with systemic amyloidosis. The TTR 
amyloidosis, including familial amyloidotic polyneuropathy (FAP) and 
cardiomyopathy (FAC), are caused by mutation of the TTR gene. Up to date, more 
than 80 point mutations of TTR have been identified and most of them were revealed 
associated with FAP. Only about 12 of the mutations are nonpathogenic (Connors 
et al., 2003; Saraiva, 2001). The mutate TTRs have been reported to be the non-
causative molecules for the senile systemic amyloidosis (SSA). However, this disease 
is a sporadic disorder resulted from deposition of the wild-type TTR fibril in cardiac 
and other tissues. 
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Table 1.1  Human amyloid fibril proteins and their precursors (Source : 
Westermark et al., 2002) 
Amyloid 
protein Precursor 
Systemic (S) 
or Localized 
(L) 
Syndrome or tissue of 
deposition 
 
AL 
 
AH 
 
ATTR 
Aß2M 
AA 
AApoA-I 
AApoA-II 
AGel 
ALys 
AFib 
ACys 
ABri 
ADan 
 
Aß 
APrP 
ACal 
AIAPP 
AANF 
APro 
AIns 
AMed 
Aker 
A(tbn) 
ALac 
 
Immunoglobulin light 
chain 
Immunoglobulin heavy 
chain 
Transthyretin 
β2-microglobulin 
(Apo)serum AA 
Apolipoprotein A-I 
Apolipoprotein A-II 
Gelsolin 
Lysozyme 
Fibrinogen α-chain 
Cystatin C 
ABriPP 
ADanPP 
Aβ protein precursor 
 (AβPP) 
Prion protein 
(Pro)calcitonin 
Islet amyloid 
polypeptide 
Atrial natriuretic factor 
Prolactin 
Insulin 
Lactedherin 
Kerto-epitelin 
To be named 
Lactoferrin 
 
S, L 
 
S, L 
 
S 
S 
S 
S 
S 
S 
S 
S 
S 
L 
L 
 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
L 
 
Primary, Myeloma associated 
 
Primary, Myeloma associated 
 
Familial, Senile systemic 
Hemodialysis 
Secondary, reactive 
Familial 
Familial 
Familial 
Familial 
Familial 
Familial 
Familial dementia 
Familial dementia 
 
Alzheimer’s disease, aging 
Spongioform encephalopathies 
C-cell thyroid tumors 
Islets of Langerhans 
insulinomas 
Cardiac atrial,  
Aging pituitary, Prolactinomas 
Iatrogenic 
Senile aortic, media 
Cornea; Familial 
Pindborg tumors 
Cornea; Familial 
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3.3.1 Familial amyloidotic polyneuropathy (FAP) 
 
FAP is the most common hereditary systemic amyloidosis. It is 
identified as an autosomal dominant disorder with peripheral sensory motor and 
autonomic neuropathy (Andrade, 1952). It is well known that the amyloidogenic TTR 
is a major constituent of the amyloid that deposits in tissue of the FAP patients. The 
disorder of FAP was first observed in the Portuguese (Andrade, 1952). The amyloid 
fibrils were shown extracellularly systemic deposited throughout the connective tissue 
with the exception of brain and liver parenchyma. It affected particularly the 
peripheral nervous system (Coimbra and Andrade, 1971a, b) and led to dysfunction of 
organs and ultimately death. The symptom onset of FAP usually occurs in the third to 
the forth decade of life. The symptom usually begins with a neuropathy of the sensory 
peripheral in lower limbs following by the motor impairments, which leads to wasting 
and weakness (Andrade, 1952; Booth et al., 1998; Misrahi et al., 1998). Most of FAP 
patients involve with an early and severe autonomic nervous system, commonly 
manifested by dyshydrosis, sexual impotence, alternating diarrhea and constipation as 
well as orthostatic hypotension and urinary bladder dysfunction (Canijo and Andrade, 
1969; Guimarães et al., 1980; Alves et al., 1997b; Ando and Suhr, 1998). 
The biochemical nature of amyloid deposits was elucidated. It 
showed mutated TTR as the main protein constituent of the amyloid deposits in FAP 
(Costa et al., 1978). Amongst, TTR V30M is the most common and has been found 
throughout the world, however, in endemic areas. It is frequently found in northern of 
Sweden (Andersson, 1976; Holmgren et al., 1994), northern of Portugal (Andrade, 
1952; Alves et al., 1997a), and Japan (Araki et al., 1968; Araki, 1984). Prevalence and 
age of the disease onset vary among and within populations. In Portugal, prevalence 
of V30M is high and the symptoms typically develop before the age of 40 years 
(Sousa et al., 1995). A slightly lower prevalence, to approximate 5%, and later onset, 
usually after the age of 50 years, of the disease was reported in Swedish carriers 
(Andersson, 1976; Sousa et al., 1993). Onset of the disease reported in the Japanese 
was either early or late (Tashima et al., 1995). Incidentally, the V30M homozygous 
did not show more severe form of FAP or some did not, even, develop FAP 
(Holmgren et al., 1988; Yoshinaga et al., 1992), indicating that mutation itself is 
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necessary but not sufficient to cause FAP. Other unidentified genetic or environmental 
factors were suggested contribute to the pathogenesis of the disease. 
Up to date, more than 80 mutations of TTR gene have been reported 
in association with human amyloidosis (see Table 1.2) (Saraiva, 2001), and most of 
them are connected to FAP with an indistinguishable clinical symptom from the 
original description of the disease (Toyooka et al., 1995; Booth et al., 1998; Misrahi et 
al., 1998; de Carvalho et al., 2000). Whereas, the others may contribute to a variety of 
phenotype including simultaneous neuropathy and cardiomyopathy, carpal tunnel 
syndrome, predominance of vitreous TTR deposition, and involvement of 
leptomeningeal. Only a few TTR mutations are related to cardiomyopathy without 
neurological symptoms. The most common TTR mutation associated with familial 
cardiac amyloidosis (FAC) is V122I, frequently found in the African-Americans. The 
allele frequency of V122I among the population was about 12% (Jacobson et al., 
1997) 
Among the TTR mutations, some have been reported to appear as 
non-amyloidogenic (see Table 1.3). Frequency of each allele is varied in different 
populations. For examples, Gly6Ser (G6S; substitution of glycine by serine at amino 
acid position 6) is present about 12% of the Caucasian population, while, Thr119Met 
(T119M; substitution of threonine by methionine at amino acid position 119) is found 
to about 0.8% of Portuguese and German populations. However, in some cases where 
both pathogenic and non-pathogenic mutations occurred, the non-pathogenic mutation 
apparently inhibited the development of FAP (Coelho et al., 1996) 
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Table 1.2 TTR amyloidogenic variants (Source: Saraiva., 2001) 
Muatation       Codon change 
   Predominant 
  clinical feature 
         Origin 
 
Cys10Arg  
 
TGT  
 
CGT  
 
PN, AN, Eye  
 
Hungary  
Leu 12Pro  CTG  CCG  LM, PN, AN  UK  
Asp18Glu  GAT  GAG  PN, AN  Columbia  
Asp18Gly  GAT  GGT  LM  Hungary  
Val20Ile  GTC  ATC  Heart  Germany  
Ser23Asn  AGT  AAT  Heart  Portugal  
Pro24Ser  CCT  TCT  Heart, CTS, PN  USA  
Val28Met  GTG  ATG  PN, AN  Portugal  
Val30Met  GTG  ATG  PN, AN, Eye  Several  
Val30Ala  GTG  GCG  Heart, AN  Germany  
Val30Leu  GTG  CTG  PN, AN  Japan  
Val30Gly  GTG  GGG  LM, Eye  France  
Phe33Ile  TTC  ATC  PN, Eye  Poland  
Phe33Leu  TTC  CTC  PN, AN  Poland  
Phe33Val  TTC  GTC  PN, AN  UK  
Arg34Thr  AGA  ACA  PN, Heart  Italy  
Lys35Asn  AAG  AAC  PN, AN, Heart  France  
Ala36Pro  GCT  CCT  PN, Eye  Greece  
Asp38Ala  GAT  GCT  PN, Heart  Japan  
Glu42Gly  GAG  GGG  PN, AN  Japan  
Glu42Asp  GAG  GAT  Heart  France  
Phe44Ser  TTT  TCT  PN, AN, Heart  Ireland  
Ala 45Asp  GCC  GAC  Heart  Italy  
Ala45Ser  GCC  UCC  Heart  Sweden  
Ala45Thr  GCC  ACC  Heart  Italy  
Gly47Arg  GGG  CGG  PN, AN  Japan  
Gly47Ala  GGG  GCG  Heart, PN, AN  Italy  
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Table 1.2 (continued) 
 Mutation        Codon change 
 
Predominant 
clinical feature           Origin  
 
Gly47Glu  
 
GGG  
 
GAG  
 
PN  
 
Germany  
Thr49Ala  ACC  GCC  Heart, PN  Italy  
Thr49Ile  ACC  ATC  PN, Heart  Japan  
Ser50Arg  AGT  AGG  PN, AN  Japan  
Ser50Ile  AGT  ATT  Heart, PN, AN  Japan  
Glu51Gly  GAG  GGG  Heart  USA  
Ser52Pro  TCT  CCT  PN, AN, Heart  UK  
Gly53Glu  GGA  GAA  LM, Heart  France  
Glu54Gly  GAG  GGG  PN, AN  UK  
Glu54Lys  GAG  GAA  PN, AN, Heart  Japan  
Leu55Arg  CTG  CGG  LM, PN  Germany  
Leu55Pro  CTG  CCG  PN, Heart, AN  Taiwan  
His56Arg  CAT  CGT  Heart  USA  
Leu58His  CTC  CAC  CTS, Heart  Germany  
Leu58Arg  CTC  CGC  CTS, AN, Eye  Japan  
Thr59Lys  ACA  AAA  Heart, PN  Italy  
Thr60Ala  ACT  GCT  Heart, CTS  Ireland  
Glu61Lys  GAG  AAG  PN  Japan  
Phe64Leu  TTT  CTT  PN, CTS, Heart  Italy  
Phe64Ser  TTT  TCT  LM, PN, Eye  Italy  
Ile68Leu  ATA  TTA  Heart  Germany  
Tyr69His  TAC  CAC  Eye  Scotland  
Lys70Asn  AAA  AAC  CTS, PN, Eye  Germany  
Val71Ala  GTG  GCG  PN, Eye  Spain  
Ile73Val  ATA  GTA  PN, AN  Bangladesh  
Ser77Phe  TCT  TTT  PN  France  
Ser77Tyr  TCT  TAT  PN  Germany  
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Table 1.2 (continued) 
 
 Mutation        Codon change 
 
Predominant 
clinical feature 
          Origin  
 
Ile84Asn  
 
ATC  
 
AAC  
 
Eye, Heart  
 
Italy  
Ile84Thr  ATC  ACC  Heart, PN, AN  Germany  
Glu89Gln  GAG  CAG  PN, Heart  Italy  
Gku89Lys  GAG  AAG  PN, Heart  USA  
Ala91Ser  GCA  TCA  PN, CTS, Heart  France  
Ala97Gly  GCC  GGC  Heart, PN  Japan  
Ala97Ser  GCC  TCC  PN, Heart  France  
Ile107Val  ATT  GTT  Heart, CTS, PN  Germany  
Ile107Met  ATT  ATG  PN, Heart  Germany  
Ala109Ser  GCC  TCC  PN  Japan  
Leu111Met  CTG  ATG  Heart  Denmark  
Ser112Ile  AGC  ATC  PN, Heart  Italy  
Tyr114Cys  TAC  TGC  PN, AN, Eye  Japan  
Tyr114His  TAC  CAC  CTS  Japan  
Tyr116Ser  TAT  TCT  PN, CTS  France  
Ala120Ser  GCT  TCT  Heart, PN, AN  Africa  
Val122Ile  GTC  ATC  Heart  Africa  
Val122del  GTC  Loss  Heart, PN, CTS  Equador/Spain  
Val122Ala  GTC  GCC  Heart, Eye, PN  UK  
 
AN, autonomic neuropathy; CTS, carpal tunnel syndrome; Eye, vitreous deposition;  
PN, peripheral neuropathy; LM, leptomenigeal amyloid; Heart; cardiomyopathy. 
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Table 1.3 TTR non-amyloidogenic variants 
 
 
Gly6Ser, Met13Ile, Asp74His, His90Ans, Gly101Ser, Pro102Arg, Arg104Cys, 
Arg104His, Ala109Thr, Ala109Val, Thr119Met, Pro125Ser 
 
 
 
3.3.2 Senile systemic amyloidosis (SSA) 
 
Senile systemic amyloidosis (SSA) is the most common amyloidosis 
caused by the deposition of wild-type TTR (wtTTR) fibrils. It is the most prevalent 
systemic form of amyloidosis, at least in the western. Screening of Swedish and 
American above 80 years of age revealed that 25% to 28% of the people showed some 
degree of the disease (Westermark et al., 1979; Cornwell et al., 1983; Westermark et 
al., 1990). However, it was rarely seen in individuals younger than 70 years (Röcken 
et al., 1994). Pathogenesis of the TTR amyloid deposits are commonly found not only 
in heart, but also in lungs, blood vessels and the renal medulla of kidneys 
(Westermark et al., 2003). SSA is typically manifested by cardiac disorders with 
congestive heart failure, arrhythmia and conduction blocks, and sometimes carpal 
tunnel syndrome. 
The pathogenesis of SSA is unknown. There is no mutation 
(Westermark et al., 1990; Gustavsson et al., 1995) and no evidence of over-expression 
of the TTR gene. On the other hand, the level of TTR in plasma slightly decreased in 
SSA (Westermark et al., 1985). Most of the TTR molecules found in the fibril of SSA 
are fragmented, leading to a postulation on an important role of fragmentation in 
pathogenesis of the SSA (Felding et al., 1985; Westermark et al., 1990; Westermark 
et al., 2003). The fragmentation of TTR molecule is not a random process because all 
of cleaved peptide bonds are situated within the C-strand, C-D loop and D-strand of 
the TTR polypeptide. However, it is not known whether the proteolytic cleavage plays 
a role in formation of TTR fibrils or merely represents a phenomenon of the post-
amyloidogenic. Some post-translational modifications of wtTTR such as S-sulfonation 
and thiol-conjugation of the cysteine residue at position 10 of the TTR polypeptide 
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have been implied to increase amyloidogensesis (Kishikawa et al., 1999; Suhr et al., 
1999). 
 
3.4 Fibrillogenesis of TTR 
 
Several different forms of TTR have been suggested as precursors of 
the TTR amyloids. These include monomer, whole dimer, truncated dimer and 
tetramer forms (Lai et al., 1996; Lashuel et al., 1998; Schormann et al., 1998; Quintas 
et al., 1999; Eneqvist et al., 2000; Quintas et al., 2001; Serag et al., 2001). Several 
models of TTR amyloid formation have been proposed. However, in general, all of 
them were originated primarily on the formation that begins with the disruption of the 
protein tetramer into monomers (Figure 1.14). Tetramer has been believed separating 
into AB and CD dimers that further rapidly dissociate into monomers. Neither 
dissociation into AC- and BD-dimers nor sequential dissociation into monomers was 
suggested. These monomers are, then, undergo a conformational change, which 
promotes the formation of the amyloid fibrils (Figure 1.14) (McCutchen and Kelly, 
1993; Lai et al., 1996; Kelly, 1998; Nettleton et al., 1998; Quintas et al., 1999; Jiang 
et al., 2001; Wiseman et al., 2005; Foss et al., 2005).  
Three dimensional studies by X-ray crystallography of TTR structure 
suggested that several mutations of TTR polypeptide would destabilize the native 
tertiary structure of the protein. The largest change in the tertiary structure was 
observed in Leu55Pro (L55P; substitution of leucine by proline at amino acid position 
55). This finding is related to the clinical observation showing high tendency in 
amyloidogenic fibrillar forming of L55P (Sebastião et al., 1998). It was also shown 
that the mutations are predominantly situated in the hydrophobic core of TTR. The 
mutation was usually concentrated within C-strand, C-D loop and D-strand of each 
TTR monomer (Serpell et al., 1996; Eneqvist and Sauer-Eriksson., 2001), and has 
been suggested involving in the structural changes required for amyloid formation 
(Lai et al., 1996). Not all of TTR mutations lead to the disease. Some mutations were 
reported increase stability of the tetrameric structure of TTR. The in vitro studies on 
double mutations such as V30M/T119M showed that these variants exhibited stability 
of the tetramer very close to that of the wtTTR (Almeida et al., 2000). 
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Figure 1.14 The proposed pathway of TTR fibril formation 
Native TTR tetramer dissociates into unfolded TTR monomers, which 
self-aggregated originating non-fibrillar TTR aggregates, protofibrils 
and mature amyloid fibrils.  
(Source: Sousa, 2003) 
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Although liver transplantation seems to be the only capable method of 
preventing progression of the disease, considerable risks for the patients and only 
slight improvements in neurological function are the limits (Lewis et al., 1994). Less 
invasive therapies that target to reduce amount of amyloid in organs such as 
preventing the dissociation of TTR tetramer into monomers and disrupting the 
amyloid aggregates is being pursued (Figure 1.15). Several small molecules such as 
tetracycline and T4 that show ability in binding to the thyroid hormone binding 
channel of TTR have been demonstrated to stabilize the TTR tetramer and inhibit 
dissociation into monomer species (Miroy et al., 1996; Peterson et al., 1998; Almeida 
et al., 2004). These molecules were demonstrated to inhibit oligomers of both wtTTR 
and TTR variants such as V30M and L55P in vitro (Miroy et al., 1996; Peterson et al., 
1998; Almeida et al., 2004). 
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Figure 1.15 Potential molecular therapies for the TTR amyloidoses.  
Procedures that might block the amyloidogenicity of TTR include (a) 
inhibition of synthesis of mutated TTR, (b) stabilization of the soluble 
circulating amyloid precursor, (c) inhibition of aggregation of the 
amyloidogenic intermediates and (d) disruption of the insoluble 
deposits. 
(Source : Saraiva, 2002) 
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Objectives 
1. Screening for ApoE genotype and allele variant in Thai people 
2. Screening for and characterize TTR variant in Thai people 
 
CHAPTER 2 
 
MATERIAL AND METHOD 
 
 
1. Materials 
 
1.1 Instruments 
 
Instrument Model Company 
 
Autoclave 
Automat DNA sequencer 
Balance (4 digit) 
Balance (2 digit) 
Centrifuge 
Centrifuge 
Gel Document (Labworks 4.0) 
Gel Document 
Horizontal Electrophoresis 
Incubator 
Microcentrifuge 
Microcentrifuge 
Micropipettes 
Micropipettes 
Micropipettes 
Microtome 
Microtome blade 
Oven 
Orbital shaker 
Orbital shaker 
Orbital shaking incubator 
PCR 
PCR 
 
ES-315 
ABI PRISM 377 
AB204-S 
PG5002-S 
5804R 
18/80(MSE) 
C-80 
Biodoc-It™ System 
B1 
 
260D 
SD220 
 
 
 
 
 
240 litre 
SH 30 
MS-OR 
013422 
Master cycle 
PTC-200 
 
Tomy 
Applied Biosystem 
Mettler 
Mettler 
Eppendorf 
Harrier 
UVP 
UVP 
Owl Scientific 
Memmert 
DENVILLE 
Clover 
Gilson, Labnet, 
Labmate, Nichipet, 
SOCOREX 
Reichert 
Reichert 
Binder 
FINEPCR 
Major Science 
Paton scientific 
Eppendorf 
MJ RESERCH 
54 
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Instrument Model Company 
 
pH meter 
Power supply 
Power supply 
Power supply 
Surgical blade 
Slab gel electrophoresis  
Slab gel electrophoresis  
Slab gel electrophoresis  
Spectrophotometer 
Spectrophotometer 
Spectrophotometer 
Stirrer 
Vortex mixer 
Water bath 
Water bath 
Water bath 
 
713 
ELITE 300 plus 
PAC 3000 
MP-300N 
 
MINI PROTEIN II  
MINI PROTEIN III 
AE-6450 
8453 
Thermo spectronic 
UV-160A 
 
VX100 
 
EcoTempTW20 
WB-710M 
 
Metrohm 
Wealtec 
Bio-Rad 
Major science 
Parabola 
BIO-RAD  
BIO-RAD 
ATTO corporation  
Hewlett-Packard 
GENESYS 20 
Shimadzu 
Corning 
Labnet 
GallenKamp 
Julabo 
OPTIMA 
 
 
1.2 Chemicals 
 
1.2.1 Analytical grade 
 
Chemical Company 
 
Absolute ethanol 
Acetic acid  
Acrylamide 
Agar 
Ammonium persulphate 
Bis-acrylamide 
 
BDH 
Lab Scan 
Fluka 
Merck 
 
Fluka 
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Chemical Company 
 
Boric acid 
Calcium chloride  
D-glucose 
Dimethylsulfoxide (DMSO) 
Dipotassium hydrogen phosphate 
Dithiothreitol 
Ethylene diamine tetraacetic acid (EDTA)  
Formaldehyde 
Formamide 
Glycerol 
Hydrochloric acid  
Methanol 
Phenol:chloroform:isoamyl alcohol (25:24:1) 
Silver nitrate  
Sodium acetate 
Sodium carbonate 
Sodium chloride 
Sodium dodecyl sulfate (SDS) 
Sodium hydroxide 
Sucrose 
Tris (Hydoxymethyl)- methylamine 
Tryptone 
Tween Twenty (Tween 20) 
Xylene 
Yeast extract 
 
Merck 
Merck 
Univar 
AMRESCO 
Univar 
Bio-Rad 
Carlo 
Sigma 
Sigma, AMRESCO 
BHD, Univar 
Merck  
Lab Scan, Merck 
Sigma 
Carlo, Merck 
CARLO EBRA 
Ajex, Merck 
Lab Scan 
Finechem 
Lab Scan 
USB 
USB 
Merck 
APS Finechem 
Lab Scan 
Merck 
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1.2.2 Molecular biology grade 
 
Chemical Company 
 
Agarose 
Ampicilin 
BamH I 
Deoxynucleotide triphosphate 
10 bp DNA ladder 
100 bp DNA ladder 
EcoR I 
Ethidium bromide 
Hha I 
Hind III 
Lambda DNA 
pGEM-T Easy  
Proteinase K 
Sal I 
T4 DNA ligase 
T4 DNA kinase 
Taq DNA polymeras 
X-gal 
 
Gene Pure LE 
Calbiochem 
GIBCO 
Promega 
invitrogen 
NEB Biolabs, Promega 
GIBCO, NEB Biolabs 
Promega 
NEB Biolabs 
NEB Biolabs 
NEB Biolabs 
Promega 
Invitrogen 
NEB Biolabs 
NEB Biolabs, Promega 
Promega 
Invitrogen 
Promega 
 
 
1.2.3 Reagent kits 
 
  Reagent Company 
   
Qiagen®PCR cloning kits  
QIA kit for plasmid purification    
QIA kit for PCR purification     
QIA kit for gel extraction  
 
QIAGEN 
QIAGEN 
QIAGEN 
QIAGEN 
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1.3  Samples 
1.3.1 Human Genomic DNA 
Human genomic DNAs (250 samples) were provided by Rajanukul 
Institute, Bangkok, Thailand, under collaboration with DR. Verayuth Praphanphoj.  
1.3.2 Embedded paraffin postmortem brain tissue 
Human embedded parafilm postmortem brain tissues (20 samples) 
were provided by Chulalongkorn Hospital, Bangkok, Thailand. 
1.3.3 Bacterial cells 
E. coli DH5α is a gift from Professor Schreiber, Australia.  
 
2. Methods 
 
2.1 DNA preparation from paraffin-embedded brain tissue 
DNA was extracted and purified from the paraffin-embedded brain 
tissues with the method described by Bonin et al. (2003). Ten of 10 μm-sections were 
cut with a microtomes (Reichert Microtome) from a paraffin wax block. To prevent 
cross contamination between samples, the microtome blade was cleaned after each 
block. The paraffin-embedded brain tissue (10 sections) was deparaffinized in a 
1.5 ml-tube with 1 ml xylene at 55oC for 15 min. Removing of the paraffin was 
performed twice. The tissues was then washed for 15 min at room temperature with 
100% ethanol and subsequently once with 70% ethanol. After air drying, the tissue 
pellets were digested with proteinase K (0.2 mg/ml) in 50 mM Tris/HCl, 1mM EDTA, 
and 0.5%Tween 20, overnight at 55°C. Then, DNA was extracted with phenol-
chloroform-isoamyl alcohol (25:24:1) and the clear aqueous phase was transferred to a 
new tube. To precipitate DNA, 0.1 volume of 3 M sodium acetate, pH 5.2, 2 volumes 
of ice-cold ethanol and 5% acrylamide solution (was used as a DNA carrier) was 
added and the solution was incubated overnight at -80°C. The DNA pellet was 
collected by centrifugation at 14,000 rpm for 20 min, and it was washed once with 
70% ethanol, dried up and dissolved in 20 µl of TE buffer (10 mM Tris, 1 mM EDTA, 
pH 8.0). The DNA were analyzed and determined for quality on 0.8% agarose gel 
stained with ethidium bromide prior to being stored at 4°C until used. 
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2.2 Amplification of ApoE and TTR gene fragments by polymerase chain 
reaction (PCR) 
Specific oligonucleotide primer sets were used in amplifying DNA 
fragments of ApoE exon4, TTR exon1, 2 and 4 genes. The nucleotide sequences of 
the primers, as previous reported (Gioia et al., 1998; Bonin et al., 2003; Nichols and 
Benson, 1990), are shown in Table 2.1.  
The PCR was performed using the purified human genomic DNAs as a 
template. The DNA (300 ng) was amplified in 100 µl of the reaction mixture 
containing buffer (20 mM Tris-HCl, pH 8.4 and 50 mM KCl), 250 mM MgCl2, 
25 mM dNTPs, 2.5 units of Taq DNA polymerase, and 25 pmol of each specific 
forward and reverse primers. For amplification of ApoE gene, 10% DMSO was 
additional added. PCR for the ApoE was started with an initial denaturation at 94°C 
for 5 min, followed by 40 cycles of denaturation at 94°C for 30s, annealing at 
annealing temperature (Ta) of the primers used (Table 2.1) for 30s and extension at 
72°C for 30s. The final extension was carried out at 72°C for 5 min. To amplify the 
TTR gene fragments, PCR was carried out as following: denaturation at 94°C for 
4 min, then 50 cycles of denaturation at 94°C for 1 min, annealing at annealing 
temperature (Ta) of the primers used (Table 2.1) for 1 min and extension at 72°C for 
1 min. The final extension was carried out at 72°C for 10 min. The PCR products 
were analyzed by electrophoresis on 1% agarose and the DNA bands were visualized 
by staining with the solution of 0.4µg/ml ethidium bromide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
60
Table 2.1 Oligonuclectide primers used for amplification of TTR exon1, 2, 4, and 
ApoE exon4 
 
PCR 
fragment 
Fragment 
size (bp) 
Type Primer sequence (5' → 3') Ta 
(°C) 
TTR 
Exon1 
291  
forward 
reverse 
CAGCAGGTTTGCAGTCAGAT 
GGTACCCTTGCCCTAGTAAT 
55 
TTR 
Exon2 
311  
forward 
reverse 
TCTTGTTTCGCTCCAGATTTC 
CAGATGATGTGAGCCTCTCTC 
58 
TTR 
Exon4 
258 
forward 
reverse 
TAGGTGGTATTCACAGCC 
GTGCCTTTCACAGGAATG 
60 
ApoE 
Exon4 
300 
forward 
reverse 
GGCACGGCTGTCCAAGGAGC 
ACGCGGCCCTGTTCCACCAG 
63 
 
2.3 Polymerase Chain Reaction-Restriction Fragment Length 
Polymorphism (PCR-RFLP) 
Polymorphism of ApoE gene was determined as described by Hixson 
and Vernier (1990) and Wenham et al. (1991). The PCR products (400 ng) of ApoE 
exon4 gene were digested with 7.5 units of restriction enzyme HhaI (New England 
Biolabs) at 37°C for 6 h. The digested DNAs were separated in 20% polyacrylamide 
gel (prepared from a stock acrylamide solution containing ratio of acrylamide and bis-
acrylamide at 38: 2) containing 10% glycerol, using the Mini PROTEIN II or III (Bio-
Rad, Hercured, CA) and TBE buffer pH 8.3, at 4°C with a constant voltage (150 volts) 
for 6 h. The temperature of the system was kept cool throughout the separation. 
Thereafter, the DNA bands were visualized by staining the gel with silver nitrate. 
 
2.4 Single-stranded conformation polymorphism (SSCP) 
SSCP was performed as described by Connor et al., 2004. In brief, 
genomic DNA was amplified for TTR exon 1, 2 and 4 by PCR using the specific 
nucleotide primer pairs (Table 2.1). Then, the PCR product (100 ng) was incubated 
with 2 volumes of the buffer containing 98% formamide, 10 mM NaOH, 10 mM 
EDTA, 0.05% xylene cyanol and 0.05% bromphenol blue, at 95°C for 10 min, before 
 
 
61
the mixture was chilled on ice and analyzed on 20% polyacrylamide gel (prepared 
from a stock acrylamide solution containing ratio of acrylamide: bis-acrylamide at 
29.2: 0.8) containing 10% glycerol. The electrophoresis separation was carried out in 
Mini PROTEIN II or III (Bio-Rad, Hercured CA) using TBE buffer pH 8.3 at 4°C 
with a constant voltage (150 volts) for 3 h. Temperature was kept cool through the run 
of gel. Thereafter, the gel was stained with silver nitrate. 
 
2.5 Cloning of PCR product  
Purified PCR product such as TTR gene fragment was ligated to the E. 
coli cloning vector, pGEM-T Easy (Promega) according to the method described by 
the company (Figure 2.1). In brief, the ligation reaction mixture (10µl in total 
volume), comprising of 20 ng of the purified DNA and 25 ng of the cloning vector, 
was incubated at 37°C for 2 min prior to chilling on ice and  2 units of T4 DNA ligase 
was added, and the incubation was continued at room temperature for 2 h. The 
reaction mixture was immediately transformed into a bacterial cell as described in 
section 2.7 or kept at 4°C until used.  
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f1 ori
LacZ
Amp pGEM-T 
Easy Vector 
ori
T
T
SP6
EcoR I 
EcoR I 
TTR gene fragment 
T7 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Cloning of TTR gene fragments for nucleotide sequencing 
pGEM-T Easy and pDrive vector were selected as vehicles to bring 
TTR exon gene into and being amplified in the E. coli cell. The vectors 
contain origin of replication of the filamentous phage f1, and T7 and 
SP6 RNA polymerase promoters flanking a multiple cloning region 
within the α-peptide coding region of β-galactosidase. The DNA 
fragment was inserted into the vector between the EcoR I sites. Priming 
between the DNA of interest with the pGEM-T Easy and the pDrive 
vector is ensured by a single 3′-T and 3′-U overhangs at the insert site, 
respectively. f1 origin represences phage f1 origin; Amp is ampicillin 
resistance gene; kanamycin is kanamycin resistance gene; lacZ is lacz 
α-peptide coding region used in selection of the blue/white colony 
screening. 
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2.6 DNA sequencing 
Nucleotide sequence of the DNA inserted plasmid or PCR product was 
determined by the Scientific Equipment Center, Prince of Songkla University (PSU) 
with the modified chain termination sequencing method of Sanger et al. (1977), using 
a Dye Terminator Cycle Sequencing Kit (Applied Biosystems). DNA was separated 
according to size in polyacrylamide gel under denaturation and the data processing 
was performed using the ABI Prism 377 Automated DNA sequencer (Applied 
Biosystems). The alignment program e.g. BLAST was used to check and compare the 
obtained nucleotide sequences. 
 
2.7 Preparation of E. coli competent cells and transformation of DNA into 
cell 
Competent cells were prepared from E. coli strain DH5α  by using 
calcium chloride as described by Cohen et al. (1972). A single colony of the freshly 
overnight grown bacteria was picked up from the Luria-Bertani (LB) agar plate and 
inoculated in 5 ml of LB broth in a 50-ml tube at 37°C. Subculturing was performed 
with 50 µl of the overnight culture, and cells were grown until OD600 of the culture 
reached 0.4 to 0.5 (2 to 3 h).  Then, cells were transferred to a polypropylene tube, 
cooled down on to 0°C and collected by centrifugation at 2,500 rpm for 10 min, at 
4°C.  All supernatant was removed and tube was inverted for 1 to 2 min to drain off 
all trace of the medium.  The cell pellet was then suspended in ice-cold 0.1 M calcium 
chloride (10 ml of the solution per 50 ml of the original culture) and cooled down to 
0°C. After removed out the salt solution by centrifugation, cells were resuspended in 
ice-cold 0.1 M calcium chloride (2 ml of the solution per 50 ml of the original 
culture). The competent cells were aliquoted and glycerol was added to the final 
concentration of 15.5% (v/v). Cells were quickly frozen in liquid nitrogen and 
immediately kept at -80°C as the glycerol stock. 
To transform a foreign DNA into the competent cell, 50 µl of the 
competent cell suspension was mixed and incubated on ice for 10 min with the DNA 
(approximately 0.5 µg) or an aliquot (10 µl) of the ligation mixture in a polypropylene 
tube. Then the cell mixture was subjected to heat-shock at 42°C for exactly 90s 
without shaking prior to cooling down on ice for 1 to 2 min. Thereafter, SOC medium 
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(100 µl) was added and the mixture was incubated at 37°C for 1 h prior being plated 
onto a LB agar supplemented with X-gal (150 µg/ml agar) and ampicillin 
(100 µg/ml agar). The cells were grown overnight at 37°C. Five to ten single white 
colonies, which were expected to contain the DNA inserted plasmid, were selected for 
the plasmid purification.  
 
2.8 Purification of PCR product  
The DNA fragment amplified by PCR was purified by using the 
QIAquick PCR Purification Kit (Qiagen) and following the protocol described by the 
company. In brief, 5 volumes of the binding buffer containing guanidine 
hydrochloride were added to the reaction mixture, and the entire mixture was applied 
onto a spin column. The DNA bound to the column while other impurities were 
washed out with the buffer containing ethanol. In the final step, the plasmid was 
eluted out with 30 to 50 µl of 10 mM Tris-HCl, pH 8.5 and stored at -20°C. 
 
2.9 Purification of DNA plasmid  
 
2.9.1 By using the QIAprep Miniprep kit 
Plasmid was isolated from bacterial cell by an alkaline lysis, using a 
QIAprep Spin Miniprep Kit (Qiagen) with a procedure recommended by the company 
(Birnboim and Doly, 1979). In brief, bacterial cells from 2 to 5 ml of an overnight 
culture with antibiotic were collected by centrifugation and resuspended in a buffer 
containing RNase A. Then, membrane of the cells was disrupted using an alkaline 
buffer for 5 min at room temperature. Thereafter, the cell lysate was neutralized and 
adjusted to be in a chaotropic salt (1.6 M guanidine hydrochloride) for binding to the 
silica material with a neutralizing buffer (4 M guanidine hydrochloride, 0.5 M 
potassium acetate, pH 4.2). The precipitates of chromosomal DNA and cell debris that 
occurred were removed by centrifugation then the supernatant was loaded onto a silica 
based membrane column. Plasmid was purified depending on its absorption to the 
surface of the silica filter and then was separated out from the unbound impurities in 
the washing step with a solution of 20 mM NaCl and 2 mM Tris-HCl, pH 7.5 in 80% 
methanol. Finally, the plasmid was eluted out from the column with 10 mM Tris-HCl, 
pH 8.5, and stored at -20°C until used.  
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2.9.2 By using a QIAquick PCR purification Kit 
Plasmid in an enzymatic reaction was purified with the same method 
that was described for purification of the PCR product (section 2.8), using a QIAquick 
PCR Purification Kit (Qiagen). 
  
2.10 Isolation and purification of DNA from agarose 
DNA plasmid or PCR product that were separated on an agarose gel 
can be isolated and purified using a QIAquick Gel Extraction Kit (Qiagen), following 
the protocol of the company. After electrophoresis, the gel containing band of the 
DNA of interest was excised with a sterile razor blade. The gel slice was, then, 
dissolved in the solution containing guanidine thiocyanate with a ratio of gel : solution 
at 1 : 3 (v/v). Thereafter, 1 gel volume of isopropanol was added and the entire 
mixture was applied onto a QIA spin column. The DNA was adsorbed onto a 
membrane of the column while the impurities were washed out with a buffer 
containing ethanol. Finally, the DNA was eluted with an appropriate volume of 10 
mM Tris-HCl, pH 8.5 and stored at -20°C until used. 
 
2.11 Restriction analysis of DNA inserted plasmid 
To determine size of the inserted DNA, the recombinant plasmid was 
digested with an appropriated restriction endonuclease. In general, the enzymatic 
reaction mixture (20 μl) was comprised of 200 to 5,000 ng of plasmid and 10 units of 
each appropriate enzyme. The reaction was then carried out at 37°C for 1.5 to 2 h 
prior analysis by agarose gel electrophoresis was performed and DNA bands were 
visualized by staining with ethidium bromide. 
 
2.12 Determination of DNA concentration 
Concentrations of the DNA samples and oligonucleotide primers were 
determined by spectrophotometric absorption at wavelength 260 nm. One OD260 was 
assumed corresponding to 50 µg/ml of double stranded DNA or 33 µg/ml of 
oligonucleotide. Purity of the DNAs was determined from the ratio of OD260/OD280 
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and the ratio in range of 1.8 to 1.9 indicating good purity of the DNAs (Sambrook et 
al., 1989). 
 
2.13 Non-denaturing PAGE 
The analysis of DNA fragments under non-denaturing condition was 
performed using vertical polyacrylamide slab gel (20% resolving gel and 4% stacking 
gel) and TBE buffer. For a particular work, glycerol was added to a final 
concentration of 10% to both resolving and stacking gels. After the separation, DNA 
bands were detected by silver staining. 
 
2.14 Silver staining 
Polyacylamide gel staining with silver nitrate was performed using the 
method of Morrissey, 1981. After electrophoresis, gel was placed in a solution 
containing 9.2% acetic acid and 45.4% methanol for 30 min and transferred to a 
solution containing 7.5% acetic acid and 5% methanol for 30 min. Then, it was rinsed 
with distilled water for 3 to 4 changes prior to being soaked in the solution of DTT 
(500 µg/ml) for 30 min. Thereafter, the solution was discarded and gel was soaked in  
0.1% silver nitrate for 20 min. To develop the gel, the solution containing 3% (v/v) 
sodium carbonate and 0.02% (v/v) formaldehyde was added, and gel was soaked until 
bands appeared. To stop the reaction, 50% acetic acid was added until air bubbles 
occurred. Gel was washed several times with distilled water prior being stored at 4°C 
in a plastic bag. The gel was photographed by gel document (Labworks 4.0, Bio-Rad). 
 
2.15 Lambda DNA/Hind III marker preparation 
The Lambda/Hind III marker was prepared by digestion of 10 μg 
Lambda DNA with 10 units of Hind III (NEB Biolabs). The DNA bands were 
determined for quality by separation on 0.8% agarose gel staining with ethidium 
bromide.  
 
CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
 
1. DNA preparation from paraffin-embedded brain tissue 
Paraffin wax embedded tissues are an extraordinary source for DNA 
molecular studies because of the availability of large pathology archives of tissues 
related to clinical cases in almost all hospital pathology departments. In addition to 
biopsy and surgical paraffin wax embedded tissues, postmortem tissues are an 
important resource, especially for rare diseases, for neuropathology studies or 
molecular epidemiology studies. However, the major difficulty in using the tissues is 
the degradation of nucleic acids, which is more extensive than in paraffin wax 
embedded tissue of biopsies or surgical specimens.  
In this thesis, genomic DNAs were succseefully prepared from the 
paraffin-embedded brain tissue of 20 Thais people whom have been diagnosed for the 
Alzheimer disease. Analysis on agarose gel of the DNA isolated from the individual 
sample showed size of the DNAs less than 23 kb, comparing to the lamda DNA 
marker (Figure 3.1). From the Human Genome Project that shotgun sequencing was 
used to generate and the whole consensus sequence of the euchromatic portion of 
human genome was determined, it revealed that size of the human genome is more 
than 3.2 billion base pairs (Venter et al., 2001). Therefore, size of the genomic DNA 
purified from the paraffin-embedded brain tissue obtained in this thesis indicating the 
degradation of the DNA during the tissue processing, which is a source of great 
variability occurred from the routine clinical laboratories without completely being 
standardized. These variability include type of the fixative solution, storage conditions 
(especially when formaldehyde solution is used), and suppliers. Fixation and storage 
tissues in the formaldehyde solution, which is routine used, for more than one week 
has been reported for nucleic acids damages as the chemical induces extensive cross-
linking of the tissue proteins leading to nucleic acid fragmentation (Lehmann et al., 
2001). Tissues are suggested to be fixed in a buffered formaldehyde solution at pH in 
a physiological range in dark for 24 h before embedding in the paraffin wax. More 
extensive degradation of DNA is usually found in the postmortem tissues because 
67 
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these tissues are usually fixed for a long period and in the non-buffered formaldehyde 
solution, which always used in the past. In the non-buffered solution, oxidation of 
formaldehyde to formic acid occurs creating an acidic environment, which is the main 
cause of the DNA degradation. Although DNA is relatively stable in mildly acidic 
solutions, protonation of the purine bases (N7 of guanine and N3 of adenine) occurs in 
the acidic environment in particular at around pH 4, leading to hydrolysis of the β-
glycosidic bond of the purine bases and easily cleavage of the purines. Once this 
occur, the depurinated sugar can isomerize into the open chain form thus increase 
susceptibility to be cleavage by hydroxyl ions of the depurinated or apurinic DNA 
(Voet et al., 1999). In average, size of the DNA isolated from the biopsy tissues is 
300-400 bp, but much shorter can obtain from the postmortem paraffin wax embedded 
tissues (Lehmann et al., 2001; Ninet et al., 1999).  
In this thesis, the spectrophotometric measurement of the absorbance at 
wavelengths of 260 nm and 280 nm was used to estimate the purity of the genomic 
DNA purified from the embedded tissues, which might have some contaminants such 
as proteins and phenol those also have the absorbance at wavelength 280 nm. A260 
and A280 are frequent used to determine the concentrations of nucleic acid and 
protein, respectively. The ratio of A260/A280 less than 1.5 suggests protein 
contamination in a nucleic acid sample (Sambrook et al., 1989). The ratio of A260/ 
A280 of the DNA samples obtained in this thesis were ~1.1 to 2.2 (data not shown). 
These might indicate contamination of some proteins as well as phenol in the DNA 
samples. However, as physicochemical alterations produced by pH and temperature, 
and chemical modification can also increase the absorbance ratio of 260/280 nm to 
more than the normal range (1.8-1.9) (Wilfinger et al., 1997; Okamoto and Okabe, 
2000; Kim et al., 2005), the quality of DNA was also assessed by agarose gel 
electrophoresis and its performance in PCR was evaluated. The analysis on agarose 
gel electrophoresis can inform not only average size, but also degradation degree of 
the DNA (Figure 3.1). 
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Figure 3.1 Mobility of human total genomic DNA on agarose gel  
Total genomic DNA (~1μg) was separated on 0.8% agarose. M, the 
DNA marker (23 kb Lambda DNA/Hind III); 1 to 6, the DNA purified 
from the individual paraffin-embedded brain tissue; 7, genomic DNA 
purified from blood. Degradation of the DNA to a smear zone was 
observed in all samples obtained from the embedded tissues but not 
from the fresh blood. 
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2. Apolipoprotein E genotyping by Polymerase Chain Reaction-Restriction 
Fragment Length Polymorphism (PCR-RFLP) 
The gene of ApoE is located on chromosome 19 containing four exons 
and spanning to 3.7 kb (Olaisen et al., 1982). Three common isoforms of ApoE, E2, 
E3 and E4, are encoded by allele ε2, ε3 and ε4 (Zannis and Breslow, 1981). These 
isoforms differ from each other at codons 112 and 158, which are encoded by exon 4 
of the ApoE gene. E2 has cysteine at position 112 and 158, while E3 has cysteine at 
position 112 and arginine at position 158, and E4 has arginine at both positions. The 
ApoE-ε3 is the most common allele in population with the frequency of about 78% in 
European and American Caucasian whereas ApoE-ε4 and ε2 represent approximately 
15% and 7% of all alleles, respectively. These 3 alleles are expressed co-dominantly 
to generate six different genotypes. While it has been reported that the ε4 allele of 
ApoE is associated with earlier age at the onset and increased risk of Alzheimer’s 
disease (AD), the ApoE-ε2 allele may reduce the risk of dementia in heterozygous 
carriers. 
In this thesis, the ApoE exon 4 was amplified from the genomic DNA 
purified from the peripheral blood of 237 individual Thai people by PCR under 
conditions as described in section 2.2. The specific oligoprimers containing nucleotide 
sequences as shown in Table 2.1 were used to amplify fragments of the gene. An 
example of the analysis on 1% agarose gel of the PCR products was shown in Figure 
3.2. Only a single band of the DNA fragment was detected from each reaction. The 
fragment sizes of the DNA were similar to that previously reported (Lynda et al., 
1998), i.e. 300 bp. Specificity of the amplification reactions was very high, evidently 
from high intensity of the amplified DNA bands obtained. These confirmed good 
quality of the purified DNA templates. 
Nowadays, genotyping of the apolipoprotein E by PCR-RFLP has been 
widely replaced the isotyping by gel electrophoresis. The molecular analysis is 
performed using a pair of specific primers to amplify region in the ApoE exon 4 that 
encodes and generates polymorphisms characteristic of the three common ApoE 
alleles. Restriction endonuclease HhaI is used to generate the DNA fragments of 
typical lengths for the ε2, ε3 and ε4 alleles. Because arginine (CGC) substitution by 
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cysteine (TGC) at codons 112 and 158 alters the HhaI (GCGC) cleavage sites, all six 
common genotypes can be distinguished by the unique combinations of the 
different-sized restriction fragments. 
In this thesis, the ApoE gene encompassing the nucleotide substitutions 
at residues 112 and 158 can be amplified by PCR with specific primers allowing each 
ApoE genotype to be identified as a specific combination of the DNA band patterns. 
The four HhaI digested fragments i.e. 91, 83, 72 and 48 bp, which are specifically 
used to differentiate six different ApoE genotypes, were clearly separated as distinct 
bands by 20% non-denaturant polyacrylamide gel electrophoresis as  shown in Figure 
3.3. Examples of the electrophoretic mobility patterns of the HhaI digested fragments 
of the ApoE exon 4 amplified from 48 individual normal people (average age is over 
60 years; used as control), 33 patients with Down’s syndrome (DS) (average age is 
12.64 ± 5.57 years; 19 males and 14 females ), 55 cases with other AD high risk 
(ADHR) (average age is 46.78±11.45 years; 19 males and 36 females)  and 101 
individuals of ADHR control (used as the control for the ADHR) (average age is 
45.31±10.81 years; 31 males and 70 females) were shown in Figure 3.4. All of these 
individual were diagnosed of diseases following standard clinical criteria. The 
distribution of ApoE allele and ApoE genotypes among the study groups is shown in 
Table3.1.  
In the normal group (n=48), the ApoE genotyping showed that  
distribution of homozygous ε3/ε3, heterozygous ε3/ε4, heterozygous ε2/ε3, 
homozygous ε4/ε4 and  heterozygous ε2/ε4 was 52.08%, 25%, 12.5%, 2.08% and 
8.33%, respectively. However, there was no ε2/ε2 genotype found in this study (Table 
3.1). The allele frequencies of ε2, ε3 and ε4 for this group were 0.10, 0.71 and 0.19 
respectively (Table3.1). 
The ApoE genotyping of the DS patients (n=33) showed 60.61% of 
ε3/ε3, 18.18% of ε3/ε4, 15.15% of ε2/ε3 and 6.06% of ε4/ε4, whereas, ε2/ε2 and 
ε2/ε4 genotype was not found (Table 3.1). The allele frequencies of ε2, ε3 and ε4 for 
this group were 0.08, 0.77 and 0.15, respectively, (Table3.1). In comparison, the 
distribution frequency of the ε4/ε4 in Thai DS patients was triple to that of the normal 
group and, interestingly, there was no ε2/ε4.  
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The distribution of ApoE genotypes in the Thai ADHR control (n= 
101) was 75.25% for ε3/ε3, 4.95% for ε3/ε4, 16.83% for ε2/ε3, 0.99% for ε4/ε4 and 
1.98% for ε2/ε4 (Table 3.1). In comparison, distribution of the heterozygous and 
homozygous ε4, i.e. ε2/ε4, ε3/ε4 and ε4/ε4 in the ADHR control were much less than 
that in the normal group. However, similar to the normal group, the ε2/ε2 genotype 
was not found in these ADHR control (Table 3.1), and the allele frequencies of ε2, ε3 
and ε4 were 0.09, 0.86 and 0.05, respectively, (Table3.1), which were similar to the 
normal group except the frequency of ε4 was almost 4 times less.  
Genotyping of the ApoE in the Thai ADHR patients (n=55) revealed 
that 67.27% was ε3/ε3, 12.70% was ε3/ε4, 14.55% was ε2/ε3, 3.64% was ε4/ε4, 
1.82% was ε2/ε4, and ε2/ε2 genotype was not found in this group (Table 3.1), 
whereas allele frequencies of ε2, ε3 and ε4 in this group were 0.08, 0.81 and 0.11 
respectively (Table3.1). In comparing to the ADHR control group, the ADHR has 
double in frequency of ε4 and triple in distribution frequency of ε4 associated 
genotype i.e. ε3/ε4 and ε4/ε4, but not ε2/ε4.  
The frequency of the ApoE genotypes as shown in Table 3.1 indicated 
that the ε3/ε3 was the most common ApoE genotype found in all of four Thai groups 
studied in this thesis. In addition, the result showed that the most common allele of 
these Thai groups was ε3. The finding that ε3/ε3 was the most common genotype of 
the Thai groups is similar to that previous reported in both healthy and elderly DS of 
other ethnics (Cosgrave et al., 1996; Seet et al., 2004). The frequencies of the other 
three genotypes i.e. ε2/ε3, ε2/ε4 and ε3/ε4 also were not much different from previous 
observed in other ethnics (Lambert et al., 1996; Seet et al., 2004; Coppus et al., 2007). 
The absence of the homozygous ε2/ε2 in all Thai groups was unexpected particularly 
when this genotype has been confirmed associate with longevity (Royston et al., 
1994). The ε2/ε2 genotype was expected to be presence at least in the normal or the 
ADHR control group. Although the data obtained here differs from that previously 
reported for other ethnics and Thai healthy (Chanprasertyothin et al., 2000), it is 
similar to that found in Thai elderly with and without dementia (Senanarong et al., 
2001). This should be convincible that the ε2 homozygous may protect the 
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development of dementia only in DS and elderly. However, effect of the sample size 
is also possible.  
The apolipoprotein E gene polymorphism has been well known as a 
risk factor for AD and associated with the early onset of the disease (Strittmatter and 
Roses, 1995; Slooter et al., 1998). In comparison to other ethnics, the Thai normal 
group examined in this research has similar frequency of ε4/ε4 (Table 3.1). However, 
the ε4 homozygous in the DS group was three times in frequency to that in the normal 
(Table 3.1). This was different from the findings in the DS from other ethnics to 
which showed similar or less ε4 homozygous frequency than the control 
(Avramopoulos et al., 1996; Cosgrave et al., 1996; Lambert et al., 1996). According 
to the association of ApoE with AD, it should convince that this Thai DS group was 
developed AD faster than DS from the other ethnics.  
The ADHR control and ADHR showed similar frequencies of ε2/ε3, 
ε2/ε4, ε3/ε3, ε2 and ε3 to other ethnics and also to the normal and the DS groups 
studied here. However, the difference in frequency was observed in ε3/ε4, ε4/ε4 and 
the ε4. The ADHR showed three times higher in frequency of ε3/ε4 than the ADHR 
control, whereas the frequency of ε3/ε4 in DS was lower than the normal group. The 
incident of ε4/ε4 in the ADHR was three times higher than in the control, ADHR 
control, similarly to that found in the DS. In addition, the frequency of the ε4 allele 
was twice of the ADHR control. These may suggest to high risk in development of 
dementia and AD in the ADHR group. However, the medical follow up as well as 
obtaining data from larger sample size are important for the accuracy in the 
statistically interpretation. In comparison to the DS from many ethnics (Royston et al., 
1994; van Gool et al., 1995; Wisniewski et al., 1995; Martin et al., 1995; Lambert et 
al., 1996; Tyrrell et al., 1998; Deb et al., 2000; Anello et al., 2001; Coppus et al., 
2006), the Thai DS showed similar allele frequency and genotypes (Table 3.2).   
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Figure 3.2 Amplification of ApoE exon4 by PCR 
PCR was used to amplify ApoE exon4 from human genomic DNA as 
described in section 2.2. The PCR products were separated by 
electrophoresis on 1% agarose gel containing ethidium bromide, and 
the DNA fragment bands were visualized under UV. M is the DNA 
marker (100 bp ladder). 1 to 9 is the PCR product amplified from an 
individual human genomic DNA sample. 
1,517
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1,000
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Figure 3.3 Polyacrylamide gel patterns of ApoE genotypes 
The ApoE gene that encompasses the nucleotide substitutions at the 
amino acid residues 112 and 158 can be amplified by PCR using  
specific primers and after analysis on polyacrylamide gel, each ApoE 
genotype can be identified as a specific combination of the DNA band 
patterns. Five genotypes i.e. ε2/ε4, ε3/ε4, ε2/ε3, ε3/ε3 and ε4/ε4, but 
not ε2/ε2, can be detected in this research. After PCR, the PCR product 
of the ApoE gene (400ng) was digested with HhaI prior to analysis by 
native PAGE (20% resolving gel). The DNA band fragments were 
visualized by silver staining as described in sections 2.4 and 2.14. 
Arrows indicate positions of the DNA fragments (91, 83, 72 and 48 bp) 
generated from the enzymatic reaction and used to identify the allele. 
M is the DNA marker (10 bp ladder). 
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Figure 3.4 ApoE genotyping of the Thai people groups 
PCR-RFLP analysis was performed to determine the genotype of 
ApoE. Only 5 ApoE genotype i.e. ε2/ε4, ε3/ε4, ε2/ε3, ε3/ε3 and ε4/ε4 
were detected in groups of normal (A), DS (B), and ADHR control and 
ADHR (C), that were studied in this thesis. Positions of the DNA 
fragments (91, 83, 72 and 48 bp) used for the allele identification are 
indicated by arrows. 1 to 7 indicates individual samples. M is a DNA 
marker (10 bp DNA Ladder). 
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Table 3.1 Distribution of the ApoE alleles in the Thai groups  
Allele frenquency 
(%) 
Genotype distribution 
(frequency in %) Group 
Age 
(mean+SD) 
 
Male/ 
Female
ε2 ε3 ε4 ε2/ε2 ε2/ε3 ε2/ε4 ε3/ε3 ε3/ε4 ε4/ε4
DS 
(n=33) 
12.64 ± 
5.57 
19/14 7.58 77.28 15.15 0 15.15 0 60.61 18.18 6.06 
Normal 
(control) 
(n=48) 
60± 22/26 10.42 70.83 18.75 0 12.50 8.33 52.08 25.00 2.08 
ADHR 
(n=55) 
46.78 ± 
11.45 
19/36 8.20 80.90 10.90 0 14.55 1.82 67.30 12.70 3.64 
ADHR 
control 
(control 
for  
ADHR) 
(n=101) 
45.31 ± 
10.81 
31/70 9.40 86.14 4.46 0 16.83 1.98 75.25 4.95 0.99 
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Table 3.2 Comparison of the ApoE allele frequencies in DS 
Allele frequency Genotype distribution 
Study  na Ageb 
ε2 ε3 ε4 ε2/ε2 ε2/ε3 ε3/ε3 ε3/ε4 ε4/ε4 ε2/ε4 
Royston et al. (1994)     DS 44 ±62.4 0.27 0.62 0.12 1 4 9 8 -     - 
Van Gool et al.(1995)  DS 104 51.9±6.2 0.09 0.80 0.12 1 6 33 11 - 1 
Wisniewski et al. (1995) DS 38 ±49.3 0.11 0.89 - - 3 16 - - - 
Martin et al. (1995) DS 46 ±46 0.12 0.70 0.18 - 6 13 3 - - 
Lambert et al. (1996)     DS 82 45.2±7.7 0.11 0.74 0.15 - 7 23 8 1 2 
Tyrrell et al. (1998)        DS 442 47.1±8.2 0.05 0.82 0.13 2 17 151 42 5 4 
Deb et al. (2000)            DS 114 51±7.8 0.03 0.85 0.12 - 3 40 14 - - 
Anello et al. (2001)        DS 120 22.1±10.5 0.03 0.92 0.04 - 4 51 5 - - 
Coppus et al. (2007)        DS 850 51.9±6.2 0.11 0.73 0.16 7 59 243 88 10 - 
This thesis  DS 66 12.64±5.57 0.08 0.77 0.15 - 5 20 6 2 - 
aNumber of alleles; bmean±S.D.; DS, Down’s syndrome 
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3. SSCP of TTR gene 
Screening for the point mutation of TTR gene was performed by SSCP 
technique, which is one of the effective methods for screening and identification of the 
sequence variations in a DNA single strand. The technique was first announced in 
1989 as a tool for detecting DNA polymorphisms, or sequence variations. The 
analysis offers an inexpensive, convenient, and sensitive way for determining genetic 
variation. Similar to restriction fragment length polymorphisms (RFLPs), SSCPs are 
allelic variants of inherited, genetic traits that can be used as genetic 
markers.  However, unlike RFLP, the SSCP analysis can detect DNA polymorphisms 
and mutations at multiple places in DNA fragments (Orita et al., 1989).  For the 
medical diagnoses, SSCP analysis is often used as a mutation scanning method to 
detect for the polymorphisms at single loci (Sunnucks et al., 2000). Within the SSCP 
technique, DNA is separated into single-strands and based on subtle differences in 
sequence, which is often a single base pair, will results in a different secondary 
structure and a measurable shift in mobility through a gel of the DNA single-strands. 
Migration of double-stranded DNA in gel electrophoresis is depended on size and 
length of the DNA strand and relatively independent on particular nucleotide 
sequence. On the other hand, very small changes in sequence, even one changed 
nucleotide out of several hundreds, can affect the mobility in gel of the DNA single 
strands. A single point mutation of TTR gene can be identified by this technique 
because of the relatively unstable nature of the single-stranded DNA. In the absence of 
a complementary strand, the single strand may undergo intra-strand base paring, 
resulting in loops and folds that give the single strand a unique three dimension 
structure, regardless of its length. A single nucleotide change could dramatically affect 
the strand's mobility through a gel by altering the intra-strand base pairing and its 
three dimension conformation (Melcher, 2000). SSCP analysis takes advantage of this 
quality of single-stranded DNA.   
In this thesis, the TTR exon1, 2 and 4 were amplified by PCR using the 
purified genomic DNA extracted from 173 Thai participants as templates with 
conditions as described in section 2.2. By the standard phenol/chloroform extraction, 
the genomic DNA obtained from whole blood and lymphoblast showed much higher 
in quality (OD260/OD280 ~1.3-2.0) than that extracted from the embedded paraffin 
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brain tissue (OD260/OD280 ~1.1-2.2). However, all these DNAs could be used as 
templates for the PCR with the specific oligonucleotide primers containing sequences 
as shown in Table 2.1. The TTR exon1 was amplified from 47 Thai normal and 35 DS 
patients, while TTR exon2 and exon4 were amplified from ADHR control and ADHR 
(TTR exon2 from 59 ADHR control and 29 ADHR; TTR exon4 from 20 ADHR 
control and 13 ADHR). In addition, TTR exon1 and exon4 were attempted to being 
amplified from the DNAs extracted from the paraffin-embedded brain tissues. 
By PCR, a single band of the DNA fragment from each reaction was 
detected after analysis on 1% agarose gel (Figure 3.5 and 3.6). The sizes of the DNA 
fragments were 291bp, 311bp and 258bp for the TTR exon1, 2 and 4, respectively, 
which were well agree with that reported previously (Bonin et al., 2003; Nichols and 
Benson, 1990). By SSCP analysis, the mobilities of most TTR exon fragments were 
similar among the normal, the DS, the ADHR control and the ADHR groups (Figure 
3.7 A-D). However, changes in mobility of TTR exon4 were detected in one ADHR 
control and one ADHR (Figure 3.7 B, C). In addition, a change in mobility of the TTR 
exon1 was observed in one DS and two normal (Figure 3.7 D). Double rather a single 
band was detected. All of these abnormal double DNA bands showed different 
mobilities i.e. one moved with the normal rate while the other moved slower or faster. 
The abnormality was confirmed to be resulted from a single mutation of the TTR gene 
by nucleotide sequencing.  
In this thesis, the electrophoretic mobility of the TTR exon1 and exon4 
amplified from the DNA extracted from the paraffin-embedded brain tissue was 
compared to those amplified from whole blood or lymphoblast cell lines (Figure 
3.7 E). However, no difference in mobility of the TTR exons could be observed.  
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Figure 3.5 Amplification of TTR gene fragments from the whole blood and 
lymphoblast DNAs 
PCR was used to amplify TTR exon1 (A), exon2 (B) and exon4 (C) 
from human genomic DNA that was extracted from whole blood or 
lymphoblast. The PCR products were then analyzed by electrophoresis 
on 1%agarose gel containing ethidium bromide, and the DNA bands 
were visualized under UV. M is a DNA marker (100 bp ladder). 1 to 8 
or 1 to 9 is the PCR product amplified from an individual genomic 
DNA sample. 
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100
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Figure 3.6 Amplification of TTR gene fragments from brain DNA 
TTR exon1 and exon4 were amplified from the genomic DNA isolated 
from brain tissue by PCR. The PCR products were analyzed by 
electrophoresis on 1%agarose gel containing ethidium bromide, and the 
DNA bands were visualized under UV. M is a DNA marker (100 bp 
DNA ladder). 1 and 2 is the TTR exon1 and 4 that amplified from the 
same genomic DNA sample. 
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Figure 3.7 SSCP analysis of human TTR exons 
SSCP analysis was performed to determine the shift in mobility due to 
conformational change of human TTR genes. The purified TTR exon 
amplified by PCR (100 ng) was denatured to a single-strand prior to 
analysis by native PAGE (20% resolving gel). The DNA bands were 
visualized by silver staining. (A) is TTR exon2 from ADHR control 
(lane 2-5) and ADHR (lane 1 and 6). (B), (C) is TTR exon4 from 
ADHR (lane3 in (B), lane4 in (C)) and ADHR control (lane 1-2, 4-7 in 
(B), lane 1-3, 5 in (C)).(D) is TTR exon1 from healthy control (lane1-
3) and Down syndrome cases (lane 4). (E) is TTR exon1 and 4 from 
different source i.e. brain tissue (lane 2; TTR exon4 and lane 4; TTR 
exon1) compared with whole blood or lymphoblast (lane 1; TTR exon4 
and lane 3; TTR exon1). M is the DNA marker (100 bp DNA ladder). 
Changes in mobility of the exons are indicated by broken circles. 
E
 M            1        2                            3       4 
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4. Cloning of TTR exons for nucleotide sequencing 
To obtain nucleotide sequences, the amplified TTR exons can be 
subjected to the sequencing directly. However, according to limit of the sequencing 
technique, sequences of the nucleotide at and flanking (~30-40 nucleotides away) the 
primer priming position can not be determined. Therefore, cloning of the amplified 
DNA into a vector and do sequencing of the DNA, while being an inserted form, is an 
effective way to obtain the whole sequence of the target DNA. In this thesis, 
nucleotide sequencing was carried out with TTR exons both as the PCR products and 
those inserted in a vector. For cloning, the PCR products were purified as described in 
section 2.8 and section 2.10 prior to insert into pGEM-T Easy vector at the EcoR I 
site(Figure 2.1, section 2.5). In vector, the DNA fragment was placed after the 
promoter of enzyme β-galactosidase (or Lac Z gene). The recombinant plasmid was 
then transformed into bacterial competent cell that prepared according to the method 
in section 2.7. The recombinant clones could be identified by blue/white screening 
using 5-bromo-4-chloro-3-indolyl- β-D-galactoside (X-gal) as the chromogenic 
substrate (Horwitz et al., 1964). The molecular mechanism of the blue/white screening 
is based on Lac operon of the E. coli. Insertion and expression of the TTR gene within 
the Lac Z gene lead to disruption of the hydrolytic activity of β-galactosidase. In the 
present of unligated vector, hydrolysis of the colorless substrate, X-gal, by the β-
galactosidase causes the characteristic blue color in the colonies. While, insertion of 
TTR gene into the Lac Z region disrupts and loses ability of the E. coli in hydrolyzing 
the X-gal. Therefore, white colonies indicate gene insertion into the Lac Z region.. 
However, a bacterial colony that contains no vector, so that can not produce the β-
galactosidase, also becomes white. However, these colonies can be suppressed by 
growing in the media supplemented with some antibiotic such as ampicillin. 
Three to five white colonies were selected for plasmid isolation by the 
alkaline lysis in which the isolation is based on a unique property of plasmid that 
rapidly anneal following denaturation, allowing it to be separated from chromosome 
of the E. coli. The TTR exon1 that inserted in the plasmid is released and size can be 
checked after digesting the plasmid with EcoR I. It showed that sizes of the inserted 
TTR exon1 was 291 kb (Figure 3.9) as expected. 
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Figure 3.8 Digestion of TTR DNA inserted plasmid by restriction 
endonuclease 
A recombinant vector (2.5 to 5.0 μg) containing TTR exon 1 was 
digested with EcoR I (10 units) prior the digestion reaction was 
analyzed on 1% agarose. M is the DNA marker (100 bp DNA ladder). 
Arrow indicates the DNA insert released out from the vector. 1 to 4 is 
an individual recombinant plasmid. 
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500 
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 In contrast to the chain-termination developed by Sanger (Sanger et 
al., 1977), the chain terminators, i.e. dideoxynucleotides (ddATP, ddGTP, ddCTP, and 
ddTTP), rather than primers were labeled and used in the dye terminator sequencing. 
The major advantage of the dye terminator sequencing is the sequencing can be 
performed in a single reaction because the four dideoxynucleotide chain terminators 
are labeled with different fluorescent dyes at which fluorescing different wavelength. 
Together with high-throughout computer-controlled DNA sequence analyzer, the 
fluorescent signals generated from the incorporation of the dideoxynucleotides are 
collected and chromatogram of the sequence is created. Nucleotide sequence of the 
TTR fragments was determined by the dye terminator sequencing method as described 
in section 2.6. Nucleotide sequence of the abnormal TTR gene fragment primarily 
screened by SSCP analysis was aligned with the sequences of cDNA and the whole 
gene of human TTR deposited in GenBank (accession no. M11518 for  TTR gene). 
The alignment showed a single base mutation occurred in the TTR intron1 rather than 
the exon1 region, at the nucleotide position 22 downstream of the 3′ end of the TTR 
exon1 (Figure 3.10). It is suggested to be a single nucleotide polymorphism (SNP), 
which C was substituted by G, of the TTR intron.  
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Figure 3.9 Single nucleotide polymorphism of TTR intron  
The DNA fragments of TTR exon1 including partial parts of 
presegment and intron1 was amplified by PCR from genomic DNA of 
DS (A) and two normal persons (B and C) were determined for 
nucleotide sequences by dye terminator sequencing. Substitution of C 
by G was detected at position 22 of all these TTR intron1. ACG in red 
box are codon coding for the amino acid at 3′end of the TTR exon1. 
Substitution of C by G at position 22 of the TTR intron1 was shown in 
black box. 
A 
B 
C 
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CHAPTER 4 
 
CONCLUSIONS 
 
1. DNA fragments of ApoE exon4, TTR exon1, exon2 and exon4 was amplified by 
PCR from 250 individual of Thai people showed single bands with the fragment 
size of 300, 291, 311, 258 bp, respectively. 
2. Most common of ApoE genotype and ApoE allele was ε3/ε3 and ε3, respectively.  
3. In this thesis, no ε2 homozygous that has been confirmed associate with longevity 
was not detected in all four Thai groups studied in this thesis, leading to a 
postulation that ε2 homozygous protect the development of dementia in only DS 
and elderly.  
4. The frequency of the ε4 homozygous in the DS was three times higher than the 
normal, differs from the findings in DS from other ethnics. It is convincible that 
the Thai DS may develop AD faster than the DS from other ethnics.  
5. The ε4/ε4 genotype in the ADHR was triple and the ε4 allele was double in 
frequency comparing to the control, suggesting high risk to develop dementia and 
AD in this Thai group. 
6. By the SSCP screening, five of the DNA samples isolated from 173 individual 
people and the paraffin-embedded tissue showed abnormal in the electrophoresis 
mobility of the TTR exon1 or exon4 fragments. The nucleotide sequencing 
revealed that three of the five were the C→G substitution SNP in TTR intron1 at 
position 22 downstream to the 3′end of the TTR exon1.  
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